TABLE OF CONTENTS

HEADER ........................................................................................................................................................................... 1
ABSTRACT ........................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY .................................................................................................................................................. 2
SUMMARY OF FINDINGS .................................................................................................................................................. 3
BACKGROUND .................................................................................................................................................................. 7
OBJECTIVES ................................................................................................................................................................... 8
METHODS ..................................................................................................................................................................... 8
RESULTS ...................................................................................................................................................................... 10
  Figure 1. ....................................................................................................................................................................... 11
  Figure 2. ....................................................................................................................................................................... 14
  Figure 3. ....................................................................................................................................................................... 15
  Figure 4. ....................................................................................................................................................................... 17
  Figure 5. ....................................................................................................................................................................... 19
DISCUSSION ................................................................................................................................................................. 20
AUTHORS’ CONCLUSIONS ............................................................................................................................................. 22
ACKNOWLEDGEMENTS ................................................................................................................................................... 23
REFERENCES ............................................................................................................................................................... 24
CHARACTERISTICS OF STUDIES ......................................................................................................................................... 28
DATA AND ANALYSES .................................................................................................................................................. 45
  Analysis 1.1. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 1: PE .......... 46
  Analysis 1.2. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 2: Mortality ...... 46
  Analysis 1.3. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 3: Lower limb thrombosis . 46
  Analysis 1.4. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 4: Major bleeding ..... 47
  Analysis 2.1. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 1: PE ................. 47
  Analysis 2.2. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 2: Mortality .......... 48
  Analysis 2.3. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 3: Lower limb thrombosis ..... 48
  Analysis 2.4. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 4: Major bleeding ...... 48
  Analysis 2.5. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 5: Non major bleeding .... 48
ADDITIONAL TABLES ..................................................................................................................................................... 48
APPENDICES ................................................................................................................................................................. 50
WHAT’S NEW ............................................................................................................................................................... 58
HISTORY ....................................................................................................................................................................... 58
CONTRIBUTIONS OF AUTHORS ........................................................................................................................................ 59
DECLARATIONS OF INTEREST ........................................................................................................................................... 59
SOURCES OF SUPPORT .................................................................................................................................................. 59
DIFFERENCES BETWEEN PROTOCOL AND REVIEW ........................................................................................................ 59
INDEX TERMS ............................................................................................................................................................... 59
Vena caval filters for the prevention of pulmonary embolism

Tim Young, Krishna Bajee Sriram

1Department of Medicine, Gold Coast University Hospital, Southport, Australia. 2Department of Respiratory Medicine, Gold Coast University Hospital, Southport, Australia

Contact address: Tim Young, timothy.young@health.qld.gov.au.

Editorial group: Cochrane Vascular Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 10, 2020.

Citation: Young T, Sriram KB. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD006212. DOI: 10.1002/14651858.CD006212.pub5.

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Abstract

Background
Pulmonary emboli (PE), or blood clots in the lungs, can be potentially fatal. Anticoagulation is the first line therapy to prevent PE. In some instances anticoagulation fails to prevent more emboli, or cannot be given because the person has a high risk of bleeding. Inferior vena caval filters (VCFs) are metal alloy devices that mechanically trap fragmented emboli from the deep leg veins en route to the pulmonary circulation. Retrievable filters are designed to be introduced and removed percutaneously. Although their deployment seems of theoretical benefit, their clinical efficacy and adverse event profile is unclear. This is the third update of a Cochrane Review first published in 2007.

Objectives
To assess the evidence for the effectiveness and safety of vena caval filters (VCFs) in preventing pulmonary embolism (PE).

Search methods
For this review update, the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched 10 September 2019) and the Cochrane Register of Controlled Trials (CENTRAL) (2019, Issue 8) via the Cochrane Register of Studies Online. The CIS also searched MEDLINE Ovid, EMBASE Ovid, CINAHL, and AMED (1 January 2017 to 10 September 2019) and trials registries to 10 September 2019.

Selection criteria
We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) that examined the efficacy of VCFs in preventing PE.

Data collection and analysis
For this update, studies were assessed and data extracted independently. We assessed study quality with Cochrane’s ‘Risk of bias’ tool and used the GRADE approach to assess the overall certainty of the evidence. The outcomes of interest were PE, mortality, lower limb venous thrombosis, filter-related complications and major bleeding.

Main results
We identified four new studies for this update, bringing the total to six included studies involving 1388 participants. The six studies were clinically heterogeneous and we were unable to carry out meta-analysis. Only two studies were considered to be both applicable in current clinical settings and of good methodological quality.

One was a randomised open-label trial studying the effect of a retrievable inferior vena caval filter plus anticoagulation versus anticoagulation alone on risk of recurrent pulmonary embolism (PE) in 399 participants over three months. There was no evidence of a difference in the rates of PE, death, lower extremity deep vein thrombosis (DVT), or bleeding at three and six months after the
Vena caval filters for the prevention of pulmonary embolism

Background

Blood clots in the lungs are called pulmonary emboli. They commonly originate in the leg or pelvic veins, where they can fragment and travel to the lungs via the inferior vena cava (IVC, large vein which carries blood from the lower body to the heart). Further emboli are usually prevented by blood thinning medications (anticoagulants). In some instances (approximately 4% of cases), anticoagulation fails, or it is too dangerous to give anticoagulation.

Vena caval filters are metal alloy devices inserted within the IVC to trap blood clots. Modern filters are 'retrievable,' allowing their removal once they are no longer required. However, a number of retrievable filters are not removed. The long-term safety profile of these devices is not known. The aim of this review was to assess the effectiveness and safety of vena caval filters. The review authors looked for studies comparing filters with no filter, and studies comparing different filter designs.

Study characteristics and key results

We included six trials with a total of 1388 participants in the review (current until 10 September 2019). There were too many differences between these studies so we could not combine the results.

Two trials were applicable in current clinical settings. One trial showed there is no clear benefit in receiving a retrievable filter for the first three months after an acute PE, for those who can receive anticoagulation, in terms of recurrent pulmonary embolism (PE), deep vein thrombosis (DVT), death or bleeding. Not all filters could be removed. Only minor complications from the filters were noted at six months.

Another study of people who had sustained multiple traumatic injuries did not show any benefit of inserting a filter three days after injury to prevent PE, or reduce deaths. Preventive anticoagulation and calf compression devices were administered to participants when possible.

We are unable to draw any conclusions from the remaining four included studies. This is because three studies are no longer clinically relevant because they utilised permanent filters which are seldom used now, or they did not use routine prophylactic anticoagulation which is current standard practice. The fourth study compared two filter types and was terminated prematurely as one filter group had a higher rate of thrombosis compared to the other filter type.

Reliability of the evidence

Two studies were relevant in current clinical contexts. The evidence presented by both of these studies is of moderate certainty. We reached this assessment because we were not able to combine the data from the studies, and because of the low numbers of participants and events involved. The studies differed in type of participants and clinical situations. There is a further need for trials evaluating the effectiveness of caval filters in people who cannot receive anticoagulation, or when PE occurs despite adequate anticoagulation.
### SUMMARY OF FINDINGS

#### Summary of findings 1. Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE

Does the use of vena caval filters prevent PE?

**Patient or population:** participants with unprovoked acute symptomatic PE and at high risk for recurrent PE

**Settings:** hospital

**Intervention:** retrievable VCF (with anticoagulation)

**Comparison:** no VCF (anticoagulation alone)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (RCTs)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PE:</strong> recurrent fatal and non-fatal PE, demonstrated by CT, pulmonary angiography or ventilation-perfusion lung scan (up to 6 months)</td>
<td>20 per 1000 (10 to 118)</td>
<td>RR 1.74 (0.52 to 5.86)</td>
<td>399 (1)</td>
<td>⊕⊕⊕⊝ moderate b</td>
<td>There was no clear difference between the VCF and no VCF group in the number of recurrent PE detected; all participants received anticoagulation.</td>
</tr>
<tr>
<td><strong>Mortality</strong> (up to 6 months)</td>
<td>75 per 1000 (56 to 197)</td>
<td>RR 1.39 (0.74 to 2.62)</td>
<td>399 (1)</td>
<td>⊕⊕⊕⊝ moderate b</td>
<td>There was no clear difference in mortality between the VCF and no VCF group; all participants received anticoagulation.</td>
</tr>
<tr>
<td><strong>Symptomatic lower extremity venous thrombosis</strong> confirmed by Doppler ultrasound or venography (up to 6 months)</td>
<td>10 per 1000 (1 to 55)</td>
<td>RR 0.50 (0.05 to 5.44)</td>
<td>399 (1)</td>
<td>⊕⊕⊕⊝ moderate b</td>
<td>There was no clear difference between the VCF and no VCF group in the number of lower limb venous thrombosis detected; all participants received anticoagulation.</td>
</tr>
<tr>
<td><strong>Filter-related complications</strong></td>
<td>-</td>
<td>-</td>
<td>399 (1)</td>
<td>-</td>
<td>Filter-related complications were not assessed in PREPIC2. It was reported that only 153/193 VCF could be removed.</td>
</tr>
</tbody>
</table>
Major bleeding\(^c\) (up to 6 months) | 75 per 1000 (32 to 133) | RR 0.86 (0.42 to 1.77) | 399 | ⬤⬤⬤moderate\(^b\) | There was no clear difference in major bleeding between the VCF and no VCF group; all participants received anticoagulation.

\(^a\) This population was reported by PREPIC2. All participants also received anticoagulation.

\(^b\) We downgraded certainty by one step due to some imprecision and risk of bias concerns (low numbers of events and open-label study design).

\(^c\) Major bleeding was defined as bleeding that contributed to death; occurred at a critical site (e.g. intracranial, intraspinal, epidural, or lung haemorrhage); led to transfusion of 2 or more units of red cells, platelets, or fresh frozen plasma; or was associated with a decrease in the haemoglobin level of more than 2 grams per decilitre within any 24 hour period after injury (Schulman 2005).

Summary of findings 2. Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE following multiple traumatic injuries

Does the use of vena caval filters prevent PE in people who have sustained multiple trauma?

**Patient or population:** participants who sustained multiple traumatic injuries\(^a\)

**Settings:** hospital

**Intervention:** retrievable VCF (with anticoagulation and IPC)\(^b\)

**Comparison:** no VCF (with anticoagulation and IPC)
### Symptomatic PE

<table>
<thead>
<tr>
<th>Event</th>
<th>Intervention Group</th>
<th>Control Group</th>
<th>RR (95% CI)</th>
<th>Evidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic PE</td>
<td>147 per 1000</td>
<td>10 per 1000</td>
<td>0.07 (0.00 to 1.18)</td>
<td>moderate</td>
<td>No evidence of a benefit from VCF in preventing PE. These data are from subgroup analysis of the participants who could only commence prophylactic anti-coagulation on, or after day 7 of injury.</td>
</tr>
</tbody>
</table>

### Mortality

<table>
<thead>
<tr>
<th>Event</th>
<th>Intervention Group</th>
<th>Control Group</th>
<th>RR (95% CI)</th>
<th>Evidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality from any cause</td>
<td>147 per 1000</td>
<td>65 per 1000</td>
<td>1.41 (0.68 to 2.90)</td>
<td>moderate</td>
<td>There was no clear survival benefit with filter insertion.</td>
</tr>
</tbody>
</table>

### Lower extremity venous thrombosis

<table>
<thead>
<tr>
<th>Event</th>
<th>Intervention Group</th>
<th>Control Group</th>
<th>RR (95% CI)</th>
<th>Evidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower extremity venous thrombosis confirmed by Doppler ultrasound or venography</td>
<td>102 per 1000</td>
<td>115 per 1000</td>
<td>1.13 (0.54 to 2.34)</td>
<td>moderate</td>
<td>This included both unilateral and bilateral thrombosis (some participants had more than one episode of DVT).</td>
</tr>
</tbody>
</table>

### Filter-related complications

<table>
<thead>
<tr>
<th>Event</th>
<th>Intervention Group</th>
<th>Control Group</th>
<th>RR (95% CI)</th>
<th>Evidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filter-related complications</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>moderate</td>
<td>Filter thrombosis was detected in 6/122 (4.9%) at time of retrieval. Endotheliasation preventing removal during first retrieval attempt in 2/122 (1.6%) Endothelisation necessitating surgical removal 1/108 (0.9%) Filter tilt was noted in 3/122 (2.5%), but no effect on function or removal was seen. All filters, bar one (121/122), were removed by day 232.</td>
</tr>
</tbody>
</table>

### Major bleeding

<table>
<thead>
<tr>
<th>Event</th>
<th>Intervention Group</th>
<th>Control Group</th>
<th>RR (95% CI)</th>
<th>Evidence</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major bleeding</td>
<td>147 per 1000</td>
<td>65 per 1000</td>
<td>1.07 (0.90 to 1.27)</td>
<td>moderate</td>
<td>There was no difference in the two groups with respect to major bleeding, with reference to both numbers, and transfusion requirements.</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
**CI:** confidence interval; **DVT:** deep vein thrombosis; **CT:** computer tomography; **IPC:** intermittent pneumatic compression; **RCTs:** randomised controlled trials; **RR:** risk ratio; **VCF:** vena caval filter

---

**GRADE Working Group grades of evidence**
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect

a This population was investigated only by Ho 2019.
b Retrievable VCF were inserted between days 3 to 6, or day 7+: all participants also received anticoagulation and IPC. The no VCF group received anticoagulation and IPC.
c We downgraded quality by one step due to some imprecision and risk of bias concerns (low numbers of events and open-label study design).
d Major bleeding was defined as bleeding that contributed to death; occurred at a critical site (e.g. intracranial, intraspinal, epidural, or lung haemorrhage); led to transfusion of 2 or more units of red cells, platelets, or fresh frozen plasma; or was associated with a decrease in the haemoglobin level of more than 2 grams per decilitre within any 24 hour period after injury (Schulman 2005).
**BACKGROUND**

**Description of the condition**

Blood clots can form anywhere in the venous circulation, but most commonly occur in the lower extremities (thigh) and pelvis. Blood clots or deep venous thrombosis (DVT) can occur under a number of different circumstances. Prolonged immobility, recent surgery, trauma, pregnancy, and oestrogen therapy are some of the temporary circumstances that make people vulnerable to blood clots or DVT. Having cancer (early or advanced stages) or an inherited hypercoagulable tendency are two of the longer-term conditions that make people vulnerable.

Deep vein thrombus can fragment and travel through the venous system to the lungs, causing pulmonary embolism (PE). The major conduit of venous drainage from the lower half of the body is the inferior vena cava. The clot(s) can detach and migrate through the vena cavae, through the right side of the heart and into the lung circulation. Large clots may lodge in the bifurcation between the right and left pulmonary (lung) arteries, resulting in haemodynamic compromise or collapse, or even death. Smaller clots travel to the pulmonary arterial branches, and the person may experience chest pain and breathlessness, and cough up blood.

Deep vein thrombus that extend into the thigh or pelvis are more likely to embolise than those that do not extend beyond the calf. Case series data indicate a rate between 27% to 60% for the risk of embolism if the clot is situated either within the inferior vena cava or the thigh or pelvic veins (Norris 1985; Radomski 1987).

Deep vein thrombosis can also occur in the upper extremity (arm) and neck. They can embolise to the heart and lungs via the superior vena cava.

The current treatment for pulmonary embolism is anticoagulation (heparin, vitamin K antagonists [warfarin, coumadin], as well as the newer direct oral anticoagulants [apixaban, dabigatran, edoxaban, rivaroxaban]). Infrequently, recurrent pulmonary emboli can occur despite therapeutic levels of anticoagulation; Douketis suggested a rate of 3.8% in a systematic review of the literature (Douketis 1998).

**Description of the intervention**

The concept of caval interruption emerged as early as the 18th century. Physicians performed the first successful surgical vena caval ligation (complete occlusion of the vena cava with sutures or external clips) in 1893. It required general anaesthesia and abdominal surgery, and was associated with considerable mortality. Anticoagulation became the mainstay of treatment in the 1950s. By the 1960s, vena caval ligation carried an operative mortality risk of 14%, and pulmonary embolism still occurred at a rate of 6% (due to the development of a large collateral circulation), with fatal embolism occurring at a rate of 2% (Greenfield 1992). In the 1970s, developers produced the first filters which could be inserted percutaneously, and these have since been used in increasing numbers. The first generation of filters were permanent implants, with later generation filters ‘retrievable’ or ‘optional’.

**How the intervention might work**

Vena caval filters may be placed in the inferior or superior vena cava to mechanically trap emboli, interrupting their course before reaching the heart and lungs (Owens 2010). These self-expanding devices most commonly resemble an umbrella in appearance. They are made from metal alloys. They can be inserted percutaneously (inserted through the skin into a large vein in the groin (femoral approach) or neck (jugular approach). Inferior vena caval filters are usually deployed below the level of the renal veins, but also have been inserted supra-renal (Kalva 2008).

Once deployed, permanent filters are left in situ; they become endothelialised, meaning they are eventually incorporated within the blood vessel wall. Retrieval (also known as optional) filters can be removed. Advances in percutaneous retrieval techniques mean that some retrievable and permanent filters can successfully be removed after a prolonged dwell period (Lessne 2015). There are currently approximately 15 filter designs, a number of which are retrievable (Rajeshekar 2013). Retrieval filters have potential advantages over permanent filters; one is the opportunity for subsequent removal if no longer needed, thus avoiding longer term sequelae of DVT. They can also be repositioned within the vena cava if significant endothelialisation has not occurred. Despite being called ‘ retrievable’, these filters can become permanent implants if their subsequent removal becomes complicated due to endothelialisation, or if there is a significant amount of trapped thrombus within the filter such that the filter cannot be retracted or snared back into its sheath, thus preventing percutaneous removal. Convertible filters are a relatively recent conical filter design, in which the filtering struts can be ‘deactivated’, or opened, percutaneously when the filter is no longer required. This results in the filtering struts lying flat against the caval vessel wall and anchoring struts, with no impendence to blood flow, and no filtering capability. Whether this mitigates the long-term rate of venous thrombosis noted with permanent filters, remains to be seen. Temporary filters are permanently attached to the end of a catheter, and no barbs or hooks are required to hold it in place (Tapson 2017). These temporary filters must be removed when the catheter is removed.

Filters do not prevent or treat pulmonary emboli; they avert major sequelae by intercepting larger clots before they reach the heart and lungs. The first line treatment for, and prevention of, venous thromboembolism (VTE) remains anticoagulation (ACCP 2012).

Filters can only be useful if placed downstream from the clot. Filters themselves are not fail-safe in preventing PE. Given their design, small emboli can still pass through the struts of a filter. The presence of clot(s) downstream may cause collaterals (circulation bypasses) to open up, thus clots may travel to the lungs by another route. Filter thrombosis is also a documented complication, whether this is due to an in situ thrombus or an entrapped clot. Clot extension could still occur at the distal end of the clot, thus propagating ‘through’ the filter. Deploying a second filter above this has been suggested, but there is no literature to support this practice.

**Why it is important to do this review**

Pulmonary embolism is a major cause of hospital morbidity and mortality. There is consensus that filters are strongly recommended for those who have a proximal DVT or PE, or both, where it is too dangerous for them to receive anticoagulation (ACCP 2012). However, there is controversy in the literature about whether other groups of people may potentially benefit from having a vena caval filter inserted (Hann 2005; Kinney 2003). These groups include:
• people with extensive trauma without established venous thromboembolism (VTE);
• people with large free-floating ilio-femoral thrombosis who do or do not subsequently receive thrombolytic therapy for this;
• people with cancer and concurrent VTE;
• pregnant women who have VTE;
• prevention in high risk situations such as bariatric surgery or orthopaedic joint replacements;
• people with proven VTE who sustain recurrent PE despite adequate anticoagulation.

Most controversial of the indications is when filters are placed for prevention, or prophylaxis, in people who do not have an established diagnosis of VTE, but are considered high risk for such.

The studies and the interventions examined in this review were to assess the efficacy and safety of filters; whether efficacy and safety varied amongst the different filter designs, and with different concurrent antithrombotic drugs.

We intended the comparisons in this review to be as follows.

• Filters versus no filter in those people for whom anticoagulation is contraindicated.
• Filters and anticoagulants versus anticoagulants alone.
• Filters with anticoagulation versus filters with no anticoagulation, seeking to answer the question as to whether long-term anticoagulation is recommended with permanent filters in situ (there is considerable debate about this (Gomes 2003)).
• Trials of filters with newer antithrombotic or anticoagulant drugs, of interest as these newer agents may have greater antithrombotic action or less haemorrhagic complications. Both of these effects are relevant to current indications for filters.
• Direct comparison of filter brands, to see if any one filter is superior in terms of its filtering efficiency or low rate of complications.

Comparisons of filters versus no filters also examine the complications arising from, and adverse effects of, having filters in situ. Pooled case series data indicate a recurrent PE rate of 2% to 5% with a fatal PE rate of 0.7%, despite the presence of a filter. The mortality rate from complications related to filter insertion is 0.12%. Filter migration has been estimated to occur at rates up to 69% and inferior vena cava perforation up to 24%, though these figures reflect radiological findings and not necessarily clinical events. Kinney reports that DVT occurs at rates up to 45.7%, and post-thrombotic syndrome up to 59% (Kinney 2003); these problems were observed more frequently with longer durations of follow-up. Experts disagree about whether these lower limb complications are the result of having a filter in situ, or are part of the intrinsic prothrombotic tendency some people have.

O B J E C T I V E S

To assess the evidence for the effectiveness and safety of vena caval filters (VCFs) in preventing pulmonary embolism (PE).

M E T H O D S

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) that studied the effectiveness of vena caval filters (VCFs) in preventing pulmonary embolism (PE). We excluded trials from the review if the participants had a life expectancy of less than four weeks when given treatment or if they had previous permanent VCF placement.

Types of participants
We considered participants for inclusion in trials if they were aged 18 or older and:

• had radiologically confirmed proximal deep venous thrombosis (DVT) or pulmonary embolism (PE), or both
• were considered to be at high risk of DVT or PE.

Types of interventions
We considered studies for inclusion with the following interventions.

• VCF versus no filter in people for whom anticoagulation was contraindicated.
• VCF and anticoagulation (heparin, low molecular weight heparin (LMWH), and vitamin K antagonists) versus anticoagulation (and no filter).
• VCF and anticoagulation versus filter with no anticoagulation.
• Permanent VCF versus temporary VCF.
• Direct comparisons between filter brands.
• VCF with newer antithrombotic drugs versus newer antithrombotic drugs (without filter).
• VCF with mechanical prophylaxis versus no filter and mechanical prophylaxis (includes graded compression stockings, intermittent pneumatic compression, venous foot pump) in people for whom anticoagulation was contraindicated.

Types of outcome measures

Primary outcomes

• PE (fatal and non-fatal) as demonstrated by computer tomography (CT), pulmonary angiography or ventilation-perfusion lung scan
• Mortality

Secondary outcomes

• Lower extremity venous thrombosis: distal (to filter) thrombosis, vena caval thrombosis as documented by ultrasonography
• Filter-related complications: mortality, embolisation, clinical perforation
• Major bleeding (as defined by the International Society of Thrombosis and Haemostasis (ISTH, Schulman 2005))
Search methods for identification of studies

Electronic searches

For this update the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials.

- The Cochrane Vascular Specialised Register (23 October 2017)
- The Cochrane Central Register of Controlled Trials (CENTRAL (2017, Issue 9)) via the Cochrane Register of Studies Online

See Appendix 1 and Appendix 2 for details of the search strategy used to search CENTRAL.

The CIS also searched the following trial registries for details of ongoing and unpublished studies (23 October 2017) using the terms ‘vena AND filter’ (see Appendix 1 and Appendix 2).

- ClinicalTrials.gov (www.clinicaltrials.gov)
- World Health Organization International Clinical Trials Registry Platform (who.int/trialsearch)
- ISRCTN Register (www.isrctn.com/)

The CIS subsequently conducted systematic top-up searches of the following databases without language, publication year or publication status restrictions.

- The Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS-Web) (searched from 1 January 2016 to 10 September 2019)
- The Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (CRS-W eb) (searched from 1 January 2016 to 10 September 2019)
- MEDLINE® (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) (searched from 1 January 2017 to 10 September 2019)
- Embase Ovid (searched from 1 January 2017 to 10 September 2019)
- CINAHL Ebsco (searched from 1 January 2017 to 10 September 2019)
- AMED Ovid (searched from 1 January 2017 to 10 September 2019)

The CIS modelled search strategies for the listed databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the Cochrane Handbook for Systematic Reviews of Interventions Chapter 6, Lefebvre 2011). Search strategies for major databases are provided in Appendix 3.

The CIS also performed top-up searches of the following trials registries on 10 September 2019.

- The World Health Organization International Clinical Trials Registry Platform (who.int/trialsearch)
- ClinicalTrials.gov (clinicaltrials.gov)

Searching other resources

The review authors also checked citations within identified studies.

Data collection and analysis

Selection of studies

Two authors (TY and KBS) independently reviewed the references identified by the searches for inclusion in the review. We contacted trial authors for further information if required.

Data extraction and management

One author (TY) independently extracted data according to the data extraction form provided by Cochrane Vascular. This was confirmed by a second author (KBS). The data collected on each trial included information on the participants, the interventions, and incidence figures of desired outcomes (as specified in Criteria for considering studies for this review).

Assessment of risk of bias in included studies

Two authors (TY, KBS) assessed all included studies for risk of bias using the criteria described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The following domains were assessed as ‘Yes’ (low risk of bias), ‘Unclear’ (uncertain risk of bias) or ‘No’ (high risk of bias).

- Randomisation sequence generation
- Concealment of allocation
- Blinding (of participants, personnel)
- Blinding (of outcome assessors)
- Incomplete outcome data
- Selective outcome reporting
- Other possible areas of bias

Measures of treatment effect

We reported the risk ratio (RR), with 95% confidence interval (CI) and hazard ratios (HR) with 95% CIs for dichotomous data as presented in the individual studies.

Unit of analysis issues

The participant was the individual unit of analysis.

Dealing with missing data

We intended to use intention-to-treat analysis and contact the study authors for further information in the case of missing data. There were no concerns regarding missing data.

Assessment of heterogeneity

We visually assessed the studies for clinical heterogeneity especially in regards to the subset of participants. Each study included a selected subset of people thought to potentially benefit from filters and could not be grouped together for meta-analysis. We did not perform heterogeneity investigations. If sufficient trials are available for analysis in future updates, we will assess the degree of heterogeneity amongst trials by using the I^2 statistic according to the formula I^2 = 100% × (Q - degrees of freedom)/Q, where Q is the Chi^2 statistic (Higgins 2011). If significant heterogeneity is present, we will calculate a summation statistic for each outcome using a random-effects model.
Assessment of reporting biases
There were insufficient studies identified to create a funnel plot to assess reporting bias.

Data synthesis
We were not able to carry out meta-analysis because of clinical differences between the studies and because individual study results were reported and described textually. Trial results will be pooled by meta-analysis if sufficient trials become available in the future. For studies which were to be presented in the 'Summary of findings' tables, we entered study data into RevMan analyses. This was to facilitate importing data to GRADEpro GDT.

Subgroup analysis and investigation of heterogeneity
Should sufficient information become available we intend to carry out subgroup analysis on:

- people who had a contraindication to anticoagulation;
- people who had another episode of PE despite being anticoagulated;
- people who had cancer and co-existing VTE;
- pregnant women who had VTE;
- people who had superior VCFs inserted for upper limb venous thrombosis;
- people who had supra-renal VCFs inserted;
- people who had filters inserted versus those receiving the newer antithrombotic drugs;
- permanent vs retrievable filters;
- comparisons between filter brands.

Sensitivity analysis
We intended to undertake sensitivity analyses to test the robustness of our results by removing studies at high risk of bias but, as no meta-analysis was possible, this was not done.

Summary of findings and assessment of the certainty of the evidence
For this update, we prepared 'Summary of findings' tables to present the main findings of our systematic review. We were unable to carry out any meta-analysis due to the clinical heterogeneity of the studies. We have therefore presented the results from the most clinically relevant studies in separate 'Summary of findings' tables. These are 'Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE' (Summary of findings 1), and 'Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE following multiple traumatic injury' (Summary of findings 2). We included the outcomes of PE, mortality, lower limb DVT, filter related complications, and major bleeding. We used GRADEpro software to create the tables (GRADEpro GDT). The GRADE criteria was then used to rank the certainty of the evidence for each outcome based on risk of bias, inconsistency, indirectness, imprecision and publication bias (Guyatt 2008). We provided reasons for downgrading the certainty of the evidence in the footnotes of the tables.

RESULTS
Description of studies
Results of the search
See Figure 1
Figure 1. Study flow diagram.

Four additional studies were included for this update (Barginear 2012; Ho 2019; PREPIC 2; Usoh 2010), and six additional studies were excluded (Bocharov 2011; NCT02201277; Pan 2019; Rajasekhar 2011; Stavropoulos 2016; Sharifi 2012). One previously ongoing study was excluded as it was terminated due to poor recruitment (NCT00423683). In total, there are therefore six included studies (Barginear 2012; Ho 2019; Fullen 1973; PREPIC; PREPIC 2; Usoh 2010); and 16 excluded studies (Bocharov 2011; Brasel 1997; Gosin 1997; Khansarinia 1995; Midy 1994; NCT00423683; NCT02201277; Pan 2019; Rajasekhar 2011; Rodriguez 1996; Rogers 1997; Rosenthal 1994; Rosner 2004; Sharifi 2012; Stavropoulos 2016; Webb 1992).

Included studies

The studies were heterogenous regarding both the participants they involved and in the interventions used.

- Anticoagulation with or without retrievable vena cava filter (VCF) in people at high risk of recurrent PE (PREPIC 2).
- VCF in people who sustained multiple trauma, with delayed initiation of prophylactic anticoagulation (Ho 2019).
- Anticoagulation with or without permanent VCF in people at high risk of recurrent PE (PREPIC).
- VCF in people with traumatic hip fractures, who did not receive anticoagulation (Fullen 1973).
• Anticoagulation with or without VCF in people who had cancer and with VTE (Barginear 2012).
• Comparison of two VCFs (Usoh 2010).

We have given summary details of the included studies in the Characteristics of included studies.

PREPIC2 was a multicentre prospective open-label randomised trial studying the effect of a retrievable inferior VCF (ALN Implants Chirurgicaux Ghisonaccia, France) plus anticoagulation versus anticoagulation alone on risk of recurrent PE in 399 participants. The filter was left in situ for three months and then retrieved. Those participants included in the trial were considered to be at high risk of recurrent PE, i.e. those with coexisting lower limb thrombosis as well as being aged more than 75 years, right ventricular dysfunction, active cancer, bilateral or iliacal DVT, or both, or cardiorespiratory compromise. Retrieval of all the in situ filters was intended to occur at three months. Both the filter and non-filter group were then followed for another three months. The primary outcome was recurrent PE at three months. Secondary outcomes were symptomatic DVT at three months, VTE at six months, major bleeding, mortality at three and six months and filter-related complications. Two hundred people were randomised to receive a filter; 193 actually received a filter. All people received parenteral anticoagulation therapy (heparins 85%, fondaparinux 15%) followed by vitamin K antagonists (89%) or LMWH (11%). Median age was 76 years. Thirty-five percent had a history of PE or DVT. Twenty-five percent had cancer.

The PREPIC study was a randomised controlled open-label trial with 400 participants from multiple (44) centres in France. Participants consisted of consecutive hospitalised people, made up of 64% males with an average age of 73 years, with documented proximal DVT or PE and considered by the referring physician to be at high risk of recurrent PE. There were numerous exclusion criteria; notably people were excluded if they failed or had contraindications to anticoagulation, or if they were pregnant. PREPIC had a 2 x 2 factorial design with interventions of (permanent) caval filter versus no filter, and low molecular weight heparin (LMWH) versus unfractionated heparin (UFH). Primary outcomes were: PE, mortality, and DVT. Secondary outcomes were: bleeding, post-thrombotic syndrome, and filter-related complications. Outcomes were assessed at 12 days, two years, and eight years. Both study groups received vitamin K antagonists for the first three months; at eight years, 35% of people in both study groups were still receiving vitamin K antagonists. Similar proportions of people in both groups wore elastic stockings (45% and 47% in the filter and no-filter group, respectively) at eight years. This study has limited generalisability as permanent filters have fallen out of favour.

Ho 2019 was an open-label randomised multicentre trial of 240 participants who sustained major trauma, with an Injury Severity Score of more than 15 and a median score of 27. Participants were allocated to filter or no filter within 72 hours of admission, as they could not receive immediate pharmacological VTE prophylaxis. Filters were subsequently inserted either at days 3 to 6, or on or after day seven after injury. All participants received pharmacologic prophylactic anticoagulation as soon as it was deemed clinically safe, and intermittent pneumatic compression was applied to the uninjured lower limb/s. Follow-up was for 90 days. Primary outcomes were death or PE at any stage during the study; secondary endpoints were incidence of PE in those who could not commence pharmacological VTE prophylaxis within 7 days, versus those who could. Anticoagulation was initiated within seven days, in 67% of people enrolled; 33% had ongoing contraindications to anticoagulation. Two filters were used - Bard Denali-retrievable in 117 (55.9%), and Cook-retrievable in 5 (4.1%).

Fullen 1973 was a quasi-randomised open-label trial with 129 participants in a single centre in the US. All participants who had a traumatic hip fracture were asked to be involved in the study. The mean ages in the filter group and control group were 69 and 67 years, respectively. The gender distribution was not documented. There seemed to be a greater proportion of people with atherosclerotic heart disease and cardiac failure allocated to the filter group. Exclusion criteria was refusal to consent to participating in the trial. People included in the trial were randomised to receive a (Mobin-Uddin, first generation) caval filter. Primary outcomes were PE on a definite, probable or possible occurrence (based on clinical, imaging and post-mortem data), and mortality. Secondary outcomes were complications from surgery or the filter. Dates of outcome assessments were not stated; investigations for pulmonary embolic disease were performed when clinically suspected. The average length of stay was 33 and 34 days between the two groups; no range values were listed. Seven people could not have internal fixation, one in the filter group and six in the control group. Filters could not be inserted into seven people randomised to the filter group. A jugular approach was used. Filters could not be placed into these seven people due to narrow central veins or difficulty negotiating the filter through the right atrium in severe kyphosis. No anticoagulation was used by any participant. Small doses of aspirin may have been taken by a number of control participants (no figure given but described as "occasional"). This trial is no longer relevant as the peri-operative preventive and treatment for DVT and PE is anticoagulation such as LMWH or UFH.

Barginear 2012 was a randomised open-label study of 64 participants who had cancer and then subsequently developed VTE. It was conducted in a single centre in the US. The treatment groups had similar baseline characteristics. The predominant cancers were solid organ (lung, breast, pancreas) with only 7% to 12% being lymphomas; staging ranged from involving the nearby lymph nodes (stage II) to metastatic disease. A small number of participants had brain metastases (9% to 15%). The majority were receiving chemotherapy (90% to 94%), and had ECOG performance scores of 0 to 3 (i.e. able to perform some self-care tasks, but not bed-bound). Both groups had DVT or PE confirmed by imaging following suspicious symptoms, and were commenced on fondaparinux (an anticoagulant). Participants were randomised to permanent filter insertion or control. Primary outcomes were filter complications, bleeding, and recurrent PEs. Outcomes were assessed by repeat imaging at days 14, 20 and 56, and clinical follow-up for up to three years.

Usoh 2010 was a randomised open-label study of 156 participants who had DVT or were at high risk of PE who received one of two currently available permanent filters. These were the Greenfield and TrapEase filters. The study was terminated early because it was apparent that there was a higher rate of symptomatic IVC/iliac vein thrombosis in participants with the TrapEase filter. The filter group was quasi-randomised. There were more participants who had malignancies and strokes in the Greenfield filter group, whereas
the TrapEase filter group had more participants who had recent surgery. Some participants could not receive anticoagulation.

**Excluded studies**

We identified six new studies for this update as excluded (Bocharov 2011; NCT02201277; Pan 2019; Rajasekhar 2011; Stavropoulos 2016; Sharifi 2012). A previously ongoing study was reassessed as excluded (NCT00423683). Sixteen studies in total were excluded and the reasons for exclusion included:

- studies designed to compare prospective interventional cohorts with historical controls (Khansarinia 1995; Rodriguez 1996; Rosner 2004)
- cost-effectiveness study (Brasel 1997)
- case series (Midy 1994; Rosenthal 1994)
- studies that did not have comparable prospective interventional and control groups; only selected high-risk people received filters, and prospective interventional cohorts were compared with historical controls (Gosin 1997; Rogers 1997)
- studies where only selected high-risk people received filters, and there were no data regarding baseline characteristics of the intervention and control groups. These people also received concurrent prophylactic anticoagulation in the setting of trauma (acetabular fracture) (Webb 1992)
- Rajasekhar 2011 was a pilot study about randomising filter placements in people who had been admitted following high-risk trauma. This was a feasibility study, and not designed to look for an outcome
- Sharifi 2012 was excluded as this was a randomised study concerning filters as an adjunct to percutaneous endovascular techniques for the treatment of lower extremity DVT. It showed an eight-fold reduction in PE (filter 1/14 vs control 8/22, P = 0.048). Five different endovascular techniques were utilised, and warrants further analysis; this is a highly specialised field, and considered outside the scope and expertise of the review
- study that was not randomised (Bocharov 2011)
- prospective cohort study of the Denali filter (Stavropoulos 2016)
- retrospective cohort analysis (Pan 2019)
- studies that were terminated early due to low recruitment (NCT00423683; NCT02201277)

Details of all excluded studies are given in the Characteristics of excluded studies.

**Ongoing studies**

Six studies have been identified as ongoing and are detailed within the Characteristics of ongoing studies table (ACTRN12612001071819; ChiCTR1900023485; NCT00588757; NCT03070834; NCT03691753; NCT03987321).

**Risk of bias in included studies**

See Figure 2 and Figure 3.
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

<table>
<thead>
<tr>
<th>Methodological Quality Item</th>
<th>Barginear 2012</th>
<th>Fullen 1973</th>
<th>Ho 2019</th>
<th>PREPIC</th>
<th>PREPIC2</th>
<th>Usoh 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): Mortality</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias): PE</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): Mortality</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias): PE</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): Mortality</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias): PE</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Other bias</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>
PREPIC, PREPIC2 were at low risk of bias in all domains except for performance bias (they were open-label studies). Ho 2019 was at low risk of bias for all domains except performance and detection bias.

In PREPIC2, randomisation was via a central voice-activated system, in randomly permuted blocks of four or six; there was further stratification according to centre and the patient’s creatinine clearance. It was an open-label study. The evaluation was blind, performed by a central adjudication committee. The inclusion criteria were stated, as were primary and secondary outcomes. The participants were followed for six months, and losses were minimal (two were lost to follow-up; both of these were in the filter group). The table of baseline characteristics showed matched intervention and control groups, as were the anticoagulation regimens between the two groups.

The PREPIC study was randomised by a centralised computer telephone system. The study was an open-label design. An independent adjudication committee who assessed all radiological and clinical outcomes was blinded to the treatment status of the participants. Baseline characteristics and co-interventions (including the proportion of people receiving vitamin K antagonists and wearing elastic stockings) were similar between the intervention and control groups. Withdrawals and dropouts were few and appropriately described in the manuscript. Participant cross-over was 10% (19 people initially assigned to the no-filter group subsequently received a filter). An intention-to-treat analysis was performed. Inclusion and exclusion criteria were clearly stated. Primary and secondary outcomes were reported.

Ho 2019 was randomised via permuted block scheme, stratified according to the trial centre. Four centres were involved. The trial was not blind to either the participants nor the treating clinicians. A CTPA was required if certain criteria were met. Routine chest imaging for PE was not done in asymptomatic people. All participants underwent doppler ultrasonography of the legs at 2 weeks; this was not specified in the original protocol. All other pre-specified primary and secondary outcomes were reported.

Fullen 1973 was at high risk of bias for randomisation, allocation and blinding (please also see comments within table) as it was randomised on the basis of hospital numbers (odd or even). The study was an open-label design. Participation in the filter group required consent and the insertion procedure. Baseline characteristics were scarce. A higher rate of atherosclerotic heart disease and cardiac failure was noted in the filter group. Co-interventions (usage of anticoagulation) was similar between the groups, as was time from admission-to-filter insertion and admission-to-fracture fixation. Seven people could not undergo fracture fixation - six of these were in the control group. It is not stated whether the outcome assessors were blinded or not. Diagnostic imaging for PE was not stated as being a routine part of the trial. The use of plain chest radiography for the diagnosis of PE is inaccurate. Follow-up was complete as this was an in-hospital population. Analysis was not by intention to treat. Inclusion and exclusion criteria were briefly stated. Primary outcomes of mortality and PE were given, as were details related to filter complications. No DVT rates were reported.

Barginear 2012 used a permuted block design to assign people to each treatment arm; the two groups did have similar baseline characteristics. It was an open-label study. Inclusion and exclusion criteria were clearly stated. Imaging was performed at baseline, at regular follow-up intervals, and if symptomatic of PE within 90 days of randomisation. Participants were followed for up to three years. It is not stated whether the radiologists and other assessors of outcome measures were blinded to the participant’s filter status. Analysis was by intention to treat. All 64 participants were followed through to the study’s end, with no loss of data. Both groups received anticoagulation with fondaparinux. Primary and secondary outcomes were reported.

Usos 2010 recruited people who had lower extremity DVT, or were at high risk of this. People who consented to be in the trial were subsequently randomised - this involved a nurse or participant to randomly choose a prelabelled card in an envelope. Inclusion and exclusion criteria were clearly stated. The study was an open-label design. Of 349 eligible people, 156 were randomised. The remainder became a prospective cohort, most declining to be in
the trial or unable to meet follow-up requirements (303 people) but lack of an available filter was the reason in 21 people. Three people received an Optease filter as this was the choice of the proceduralist, or determined by filter availability. Participants had baseline imaging as warranted by their clinical situation, with planned routine imaging at follow-up over a period of two years. Further imaging was performed if clinically indicated. It is not stated whether the outcome assessors were blinded to the participants filter status. Primary and secondary outcomes were reported. There was no difference in rates of anticoagulation between the two filter groups.

**Allocation**

PREPIC, PREPIC2, Ho 2019, and Barginear 2012 used a central computer-generated randomisation method and were at low risk of selection bias. Usoh 2010 randomised people by a nurse or participant to select an envelope with a prelabelled card inside. This was judged to be at an unclear risk of bias as it was not apparent if the envelopes were opaque. Fullen 1973 was randomised on the basis of hospital numbers (odd or even) and was at high risk of selection bias.

**Blinding**

All studies were of an open-label design and so were judged to be at high risk of performance bias. Efforts were made to blind the assessors in PREPIC and PREPIC2 so these were at low risk of detection bias. Blinding of the assessors was not stated in the other four RCTs and these were assessed as being at unclear risk (Barginear 2012; Fullen 1973; Ho 2019, Usoh 2010). In Ho 2019, all thoracic radiology was confirmed by an independent consultant radiologist, but there is no reference as to whether this person was blinded to the filter status of the participant. In Ho 2019, all deaths underwent coronial investigation, with an external examination, post-mortem CT, or autopsy if the cause of death was not evident from the medical records. There is recognition that ante-mortem vascular thrombosis and embolism can be difficult to distinguish from post-mortem thrombosis within the heart and large vessels (Sutherland 2017).

**Incomplete outcome data**

All studies were assessed as being at low risk of attrition bias. There were no losses in Barginear 2012, Ho 2019 or PREPIC; and minimal losses to follow-up in PREPIC2 and Fullen 1973. Usoh 2010 was terminated early due to the interim results indicating a higher symptomatic IVC/IV thrombosis rate associated with the Trapease filter. Overall follow-up for both groups was 12 months, with a range of 0 to 33 months. Mortality rates were reported over the entire follow-up period. Serial lower limb Doppler studies occurred in 121 participants (78.2%) during the 28-month follow-up period.

**Selective reporting**

Barginear 2012; Ho 2019; PREPIC; PREPIC2; and Usoh 2010 were all at low risk of selective reporting bias as they reported all primary and secondary outcomes. Fullen 1973 reported mortality and rates of PE.

**Other potential sources of bias**

We did not identify any other potential sources of bias in trial design or conduct in Barginear 2012; Ho 2019, PREPIC; or PREPIC2. Ho 2010 had similar rates of anticoagulation and use of intermittent pneumatic compression between the control and filter groups; both PREPIC and PREPIC2 had comparable rates of anticoagulation between the control and intervention groups.

Usoh 2010 was terminated early due to interim results and judged to be at unclear risk of other bias.

Fullen 1973 diagnosed PE based on chest X-ray (CXR), ventilation/perfusion scans, and pulmonary angiography or autopsy if necessary. This was the available imaging technology at that time, and may have under-reported the rates of thromboembolism (as compared to modern CT pulmonary angiography). The rates of PE were classified into ‘definite’ (positive angiogram, positive lung scan and negative CXR, or post-mortem diagnosis), ‘probable’ (positive CXR for PE), or ‘possible’ (signs and symptoms consistent with PE, but negative CXR, angiogram or lung scan not performed). It is beyond the scope of this review to discuss the sensitivity and specificities of a plain CXR and ventilation/perfusion scans in the detection of PE, but the rates are poorer as compared to CT pulmonary angiography. For further information, refer to the PIOPED and Greenspan 1982 reports. There was also a higher rate of ischaemic heart disease and cardiac failure in the filter group, but this did not affect the rates of death or PE in the overall outcomes.

**Effects of interventions**

See: **Summary of findings 1** Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE; **Summary of findings 2** Retrievable vena caval filters with anticoagulation compared to anticoagulation for prevention of PE following multiple traumatic injuries

We were unable to pool results as the studies were too diverse in patient populations and clinical situations so we have reported the findings below.

In order to allow comparison between the studies, the results of the studies are presented by outcome. The studies are presented in the following order:

- Anticoagulation +/- retrievable VCF in people at high risk of recurrent PE
- VCF in people who sustained multiple trauma, who had delayed initiation of prophylactic anticoagulation as a result of their injuries
- Anticoagulation +/- permanent VCF in people at high risk of recurrent PE
- VCF in people with traumatic hip fractures, who did not receive anticoagulation
- Anticoagulation +/- VCF in people who had cancer and VTE
- Comparison of two VCFs

**Pulmonary embolus (demonstrated by computer tomography (CT), pulmonary angiography or ventilation-perfusion lung scan)**

PREPIC2 reported no clear difference in recurrent PE (fatal and non-fatal) at three months (RR 1.99, 95% CI 0.5 to 7.85; P = 0.33; 1 study, 399 participants) and six months (RR 1.74, 95% CI 0.52 to 5.86; P = 0.37; 1 study, 399 participants; moderate-certainty evidence; Analysis 1.1).
Ho 2019 reported no clear difference in PE at 90 days (RR 0.07, 95% CI 0.00 to 1.18; P = 0.07; 1 study, 80 participants; moderate-certainty evidence; Analysis 2.1). These data come from the subgroup analysis of the participants who could only commence prophylactic anticoagulation on, or after, day seven of injury. It is noted that six filters at initial retrieval had clot present within them, perhaps indicating they were indeed doing what they were intended to do.

The PREPIC study demonstrated the efficacy of caval filters in preventing PE in a group of people with proximal DVT or PE and receiving concurrent anticoagulation, at eight years (filter 9/200 versus control 24/200; hazard ratio (HR) 0.37, 95% CI 0.17 to 0.79 in favour of a filter) (see Figure 4). The PREPIC study included small subgroups of people with cancer, and used four permanent filter designs. It lacked statistical power to be able to draw any conclusions. The study authors reported that day 12 PE rates did reach significance (filter 2/200 versus no filter 9/200; OR 0.22, 95% CI 0.05 to 0.90, P = 0.03); however, this trial utilised routine imaging for PE, which detected both symptomatic and asymptomatic PE. Symptomatic PE rates were filter 2/200 versus no filter 5/200. Two-year rates of symptomatic PE did not reach significance (filter 6/200 versus 12/200; OR 0.50, 95% CI 0.19 to 1.33, P = 0.16). Treatment of asymptomatic incidental PE is subject to debate and controversy. This is discussed further under Overall completeness and applicability of evidence. Analysis of the rates of PE at eight years stated they were not statistically different between the LMWH and unfractionated heparin (UFH) groups, so they were considered to be equivalent treatments (LMWH 3.9% versus UFH 5.7%, OR 0.66, 95% CI 0.26 to 1.70, P = 0.38). Both arms received the same rate of anticoagulation.

Figure 4. PREPIC study: Kaplan-Meier analysis of time to pulmonary embolism (generated by Dr H Bartlett from data provided in publications from PREPIC)

Fullen 1973 demonstrated caval filters were effective in reducing PE in a quasi-randomised trial of 129 participants with proximal femoral fractures, over a 33 to 34 day period. Anticoagulation was not given in either arm. Rates of PE were 4/41 in the filter group, and 19/59 in the control group.

Barginear 2012 showed no advantage or disadvantage for filter insertion in people who had cancer and concurrent venous thromboembolism who were anticoagulated. There was no difference in recurrence of PE between the two groups (24.8% versus 24%).

Usoh 2010 reported that there was no clear difference in recurrent PE rates with the TrapEase filter compared to the Greenfield filter (GF 18/84 versus TE 13/72, P = 0.6).

Mortality

PREPIC2 did not demonstrate any mortality or morbidity benefit in people with acute PE who were anticoagulated and who received a retrievable (ALN) filter in the first three months (RR 1.24, 95% CI 0.6 to 2.59; P = 0.56; 1 study, 399 participants), or six months (RR 1.39, 95% CI 0.74 to 2.62; P = 0.3; 1 study, 399 participants; moderate-certainty evidence; Analysis 1.2). People who had a contraindication to anticoagulation were not specifically studied.
Ho 2019 did not demonstrate any clear difference in mortality from any cause at 90 days (RR 1.41, 95% CI 0.68 to 2.90; P = 0.36; 1 study, 240 participants; moderate-certainty evidence; Analysis 2.2). The study authors reported no significant difference between the filter and control groups in terms of Injury Severity Scores, ventilation requirement, thoracic and/or abdominal visceral injuries, spinal cord injury with neurological sequelae, complex pelvic fractures, and (unilateral or bilateral) lower limb fractures.

PREPIC did not show any reduction in mortality at 12 days (filter 5/200 versus no filter 5/200), two years (filter 43/200 versus no filter 40/200) and eight years (filter 98/200 versus no filter 103/200) (HR 0.97, 95% CI 0.74 to 1.28, P = 0.83).

Fullen 1973 reported caval filters were not effective in reducing mortality in a quasi-randomised trial of 129 patients with proximal femoral fractures over a 33 to 34 day period. Mortality was 4/41 in the filter group and 14/59 in the control group. Rate of fatal PE in the filter group was 1/4, and 8/14 in the control group. There was a reduction in PE in the filter group, with the only case in the filter group occurring prior to filter insertion.

Barginear 2012 showed no advantage or disadvantage for filter insertion in people who had cancer and concurrent VTE who were anticoagulated. There was no difference in median survival between the two groups (anticoagulation only 493 days versus 266 days for anticoagulation with filter, P < 0.57 (data as per original study abstract)).

Usoh 2010 reported that there was no clear difference in mortality with the TrapEase (TE) filter compared to the Greenfield filter (GF) (GF 41/84 versus TE 25/72, P = 0.385).

Lower extremity venous thrombosis: distal (to filter) thrombosis, vena caval thrombosis (as documented by ultrasonography)

PREPIC2 did not report any difference in rates of symptomatic DVT at three months (RR 0.99, 95% CI 0.06 to 15.8; P = 1; 1 study, 399 participants), or six months (RR 0.5, 95% CI 0.05 to 5.44; P = 0.57; 1 study; 399 participants; moderate-certainty evidence; Analysis 1.3).

Ho 2019 showed no difference in the incidence of overall lower extremity thrombosis between the filter and control groups (RR 1.13, 95% CI 0.54 to 2.34; P = 0.75; 1 study, 240 participants; moderate-certainty evidence; Analysis 2.3). Likewise, no clear differences were seen between the number of unilateral (RR 1.77, 95% CI 0.68 to 4.64; P = 0.24), or bilateral thrombosis (RR 0.55, 95% CI 0.17 to 1.84; P = 0.33). Some participants had more than one episode of DVT.

Intermittent pneumatic compression (IPC) was applied (for at least one day and post-surgical fixation) in both lower limbs in 103/122 (84%) of the filter group compared to 101/118 (86%) of the control group; unilateral IPC was employed in 14/122 (12%) of the filter group, versus 18/118 (15%) of the control group. No IPC could be used in 9/122 (7%) of the filter group, and 2/118 (2%) of the control group.

At eight years, PREPIC reported a significant increase in the rate of DVT and filter thrombosis in the filter group (one or more documented episodes of DVT occurred in 57 participants (35.7%) in the filter group and 41 (27.5%) in the control group, (HR 1.52, 95% CI 1.02 to 2.27, P = 0.042)), (see Figure 5).
Figure 5. PREPIC study: Kaplan-Meier analysis of time to deep vein thrombosis (generated by Dr H Bartlett from data provided in publications from PREPIC)

Thrombosis was not reported in Fullen 1973.

Barginear 2012 did not show any clear difference in DVT rates with or without filter (anticoagulation alone 58.4% versus 64% anticoagulation with filter).

Usoh 2010 suggested a higher rate of IVC or iliac vein thrombosis with the TrapEase filter compared to the Greenfield filter (TE 5/72 versus GF 0/84, P = 0.02).

Filter-related complications: mortality, embolisation, clinical perforation

PREPIC2 did not assess filter-related complications. However, it was noted that, of the 193 people who actually received a filter, it could only be successfully retrieved in 153. There were only minor complications of the filter noted whilst in situ.

In Ho 2019, filter thrombosis was noted in 6/122 (4.9%) at the time of first attempted retrieval. Endothelialisation was a factor in removing the filter 2/122 (1.6%) and required surgical removal in 1/108 (0.9%). Filter tilt was noted in 3/122 (2.5%) but did not affect function or retrieval. In 7/122 (5.7%), more than one attempt at removal was necessary. The filter could not be removed at 90 days in 36/108 because of ongoing filter thrombosis (2 participants), difficulty gaining venous access for removal (27 participants) due to halo traction etc. One woman became pregnant and was the only loss to follow-up. Otherwise, all filters were removed by day 232.

PREPIC reported that post-thrombotic syndrome was a common complication (defined as the appearance or worsening of oedema, varicose veins, trophic disorders, or ulcers) in both groups, affecting 68% to 70% of people in each study group. No data were collected on filter-related complications. However, the sample sizes were small for rare events and therefore unlikely to be powered to detect them. Anticoagulation rates were similar in both arms.

No details about long-term complication rates were given in Fullen 1973.

In Barginear 2012, two participants in the filter group (versus none in the anticoagulation group) developed filter-related complications, including thrombosis necessitating thrombectomy in one, and continued bleeding at the insertion site with a protracted hospital admission in the other.

Usoh 2010 suggested a higher rate of IVC or iliac vein thrombosis with the TrapEase filter as opposed to the Greenfield filter (TE 5/72 versus GF 0/84, P = 0.02), but no difference in other complications.

Major bleeding

The ISTH definition of 'Major Bleeding' (Schulman 2005), which applies only to people who have not had recent surgery, is as follows:

1. Fatal bleeding; and/or
2. Symptomatic bleeding in a critical area or organ, such as intracranial (within the skull cavity), intraspinal, retroperitoneal (within the eye), retrotroperitoneal (a potential space behind the abdomen), intra-articular (occurring within a joint), pericardial (the thick membrane surrounding the heart), or intramuscular with compartment syndrome;

3. Bleeding causing a haemoglobin drop of 20 g/L or more, and requiring transfusion of two or more units of whole blood, or red cells.

PREPIC2 reported no clear difference in major bleeding at three months (RR 0.80, 95% CI 0.32 to 1.98; P = 0.62; 1 study, 399 participants) or six months (RR 0.86, 95% CI 0.42 to 1.77; P = 0.69; 1 study, 399 participants; moderate-certainty evidence; Analysis 1.4).

Ho 2019 reported no differences between the filter and control groups with respect to blood product transfusion requirements. There was also no clear difference in major bleeding between the filter and control groups at 90 days (RR 1.07, 95% CI 0.90 to 1.27; P = 0.47; 1 study, 240 participants; moderate-certainty evidence; Analysis 2.4) or non-major bleeding (RR 1.34, 95% CI 0.81 to 2.21, P = 0.26; 1 study, 240 participants; Analysis 2.5).

Note: "major bleeding" was defined as bleeding that contributed to death; occurred at a critical site (e.g. intracranial, intraspinal, epideral, or lung haemorrhage); led to transfusion of two or more units of red cells, platelets, or fresh frozen plasma; or was associated with a decrease in the haemoglobin level of more than 2 grams per decilitre within any 24 hour period after injury. Non-major bleeding was defined as bleeding that led to new medical interventions (e.g. gastrointestinal endoscopy or local or systemic drugs to control bleeding). Minor bleeding that did not result in any medical intervention was not reported.

PREPIC reported no clear difference in bleeding at two-year follow-up results (filter 17/200 versus no filter 22/200), reporting an odds ratio (OR) of 0.77, (95% CI 0.42 to 1.41, 400 participants, P = 0.41).

Fullen 1973 did not analyse this outcome, and it was not routine for the participants to receive anticoagulation.

Barginear 2012 suggested that there was no difference in bleeding (the study reported that one participant in the anticoagulation with filter group had significant bleeding, as opposed to two in the anticoagulation arm).

Usoh 2010 did not assess this outcome; some of the participants were enrolled because they had a problem with bleeding and therefore could not receive anticoagulation in the first instance.

DISCUSSION

Summary of main results

Six studies were included in this review but only two (PREPIC2; Ho 2019), were considered to be relevant to current clinical contexts.

PREPIC2 was a RCT of 399 participants, followed over six months, using retrievable filters in those at high risk of PE who could receive anticoagulation. This study showed no clear benefit in terms of PE, mortality, symptomatic lower extremity thrombosis (DVT), or bleeding (moderate-certainty evidence) in the initial three months. However, not all filters could be removed. Only minor complications from the filters were noted at six months but these people could be subject to the long-term problems associated with permanent filters.

Ho 2019 was a RCT of 240 participants who sustained multiple traumatic injuries and who had a retrievable filter inserted after three or seven days from injury, with delayed initiation of prophylactic anticoagulation. Follow-up was for 90 days. This study also did not show any evidence of a benefit in terms of symptomatic PE, mortality, lower extremity thrombosis or bleeding. One participant required surgery to remove the filter as it could not be done percutaneously. The remaining four studies were deemed not relevant to current clinical practice because they used permanent filters which are seldom used now (Barginear 2012; PREPIC, Fullen 1973), they did not use routine prophylactic anticoagulation which is current standard practice (Fullen 1973), or compared two filter types and was stopped early as one filter group had a higher rate thrombosis compared to the other filter type (Usah 2010). Their results are summarised below:

PREPIC used permanent filter designs in a group of 400 participants who had DVT and/or at high risk of PE and who could also be anticoagulated. The PREPIC study showed permanent VCFs prevented PE at eight years and an increasing incidence of DVT that correlated to the length of time the filter was in situ.

Fullen 1973 showed a reduction in PE in 129 high risk participants following a traumatic hip fracture who did not receive DVT prophylaxis. However, it was inadequately randomised, had more people unable to have surgical fixation of their fracture in the control group, and the outcome assessors were not blinded. It also used a filter that was subsequently removed from clinical use because of its occasional fatal filter embolism risk and high late caval thrombosis rate (Greenfield 1992). It has limited generalisability as it is now considered standard practice for DVT prophylaxis to be administered in people with traumatic hip fractures. Fullen 1973 has problems with selection bias as well as poorer diagnostic methods for PE. The study was also done prior to routine anticoagulation post-traumatic femoral fractures, which is now the current standard practice.

Barginear 2012 was a modest, single-centre, high-quality RCT involving 64 participants, which suggested no benefit of a permanent filter over anticoagulation in people with cancer and VTE.

Usoh 2010 was a single-centre study of 156 participants at risk of PE, who were randomised to one of two filter designs. The study was prematurely terminated when interim results indicated an increased rate of IVC/IV thrombosis with the Trapease filter group versus the Greenfield filter group over two years, but there were potential biases in participant selection.

Only preliminary conclusions regarding lack of filter efficacy in the prevention of PE can be drawn from these RCTs; further trial data would be desirable, but may be logistically challenging to achieve.

Overall completeness and applicability of evidence

PREPIC2, demonstrated there is no clear evidence of a benefit for routine retrievable filter insertion in people who are at high risk of PE, who can be anticoagulated. Ho 2019 showed no evidence of a benefit from prophylactic retrievable filter insertion in people...
with multiple traumatic injuries, deployed either after three or seven days (from insult), with concurrent but deferred initiation of pharmacological anticoagulation. As discussed above, only these two trials were considered relevant to current clinical settings. In PREPIC2, minor complications from the filters were noted at six months but these people could be subject to the long-term problems associated with permanent filters. Ho 2019 reported eventual percutaneous removal of all filters, except for two cases - one became pregnant and was lost to follow-up, and the other necessitated surgical removal. Retrieval filters have variable retrieval rates as reported in the literature, from 14% (Brown 2017) to between 88% and 100% (Imberti 2005). The true rate of filter retrieval is not known as these figures are likely to reflect publication bias. Local rates of removal are influenced by the clinical situation, the experience of the individual interventionist, and institutional protocols. With increasing expertise, and the development of advanced retrieval techniques, allowing the extension of the (manufacturer’s) recommended implantation period, this facilitated the scenario in which the filter was indicated to resolve or diminish; before this, their retrieval would be compromised. It is envisaged that retrievable filters may avoid the long-term thrombogenic problems seen with permanent filters but this remains to be seen.

In the PREPIC study, the group of people who received filters in the study varied significantly from the wider application in current clinical practice, notably those patients with DVT or PE, but excluded those in whom anticoagulation had failed or could not be administered. In addition, the PREPIC study used permanent filters. This limits the generalisability of the study’s conclusion. There is an increasing trend towards the use of retrievable filters in practice, although it would seem many of these are left in situ (Karmy-Jones 2007). The PREPIC study also lacked statistical power to detect a reduction in the incidence of pulmonary embolism over shorter and more clinically significant time periods. The significance of the reported reduced PE at day 12 is contributed to in part by the rates of asymptomatic PE. Incidental asymptomatic PE found on imaging for another indication is a management conundrum, with no evidence from either RCTs or large prospective trials showing a benefit from anticoagulation in people with no known VTE risk factor(s) (Chiu 2017). Filters are an adjunctive treatment with anticoagulation in patients with (or at high risk of) proximal DVT or PE. Anticoagulation remains the mainstay of treatment for venous thromboembolism (VTE) provided there are no contraindications to this.

Given the current lack of evidence in people who have a permanent filter inserted due to a perceived bleeding risk, observations from the PREPIC study suggest that consideration should be given to long-term anticoagulation when or if the risk of bleeding resolves. However, further data are required to confirm this observation. In PREPIC, caval filters were associated with an increased risk of DVT in the longer term and may be a consideration influencing the duration of anticoagulation (however, the ACCP VTE Guidelines ACCP 2016 stated the presence of a filter alone should not determine the use or duration of anticoagulation). Their use is recommended to be restricted to certain high-risk situations until more information becomes available.

No conclusions can be drawn for other subgroups of people who might benefit from filters as they have not been studied in this or any other RCT. There are several large case series reporting long-term experiences of filters for various indications but none of these studies fulfilled the inclusion criteria for this review. These groups of people include those with cancer and in pregnancy, with concurrent VTE; patients with proven DVT or PE in whom anticoagulation has failed; patients with upper extremity thrombosis and superior vena cava filters; and those with suprarenal caval filters.

The PREPIC study failed to demonstrate a survival advantage; it is noted that the majority of deaths were attributed to cancer or cardiovascular-related causes. Pulmonary embolism accounted for seven deaths, but the PREPIC study lacked statistical power to detect a difference in PE-related mortality.

Barginear 2012 showed no benefit from filter insertion in people who had cancer and acute VTE who also received anticoagulation. It was a modest trial of 64 participants, using permanent filters. Cancer staging ranged from locally advanced (stage II, involving immediately adjacent lymph node groups) to metastatic disease. To confound the current situation, the increasing use of targeted cancer immunotherapies has altered survival- and disease-free rates for certain malignancies (Carter 2020).

Fullen 1973 is no longer relevant as it is standard practice to use DVT prophylaxis to reduce PE rates in people who have sustained hip fractures.

Usoh 2010 demonstrated an increased filter thrombosis rate in the Trapease versus the Greenfield filter. There are many other filter designs available and no other trials have directly compared filters. It remains to be seen whether these double-basket filter designs have negative haemodynamics which promote filter thrombosis.

Superior vena caval filters are inserted for upper extremity thrombosis. Filters, being foreign objects within the body, potentially promote thrombosis. The superior vena cava is much shorter than the inferior vena cava, theoretically increasing the risk of clinically significant filter embolisation. Further information is needed before their placement in the superior vena cava is considered.

Quality of the evidence

Six RCTs with 1388 participants were included in this review. The studies were carried out in very different clinical situations and so were too heterogenous to pool together for meta-analyses. All were open-label studies (i.e. participants were not blinded) and were of variable methodological quality (see Figure 2 and Figure 3). Three studies were single-centre studies which were subject to significant selection, performance or detection bias (Barginear 2012; Fullen 1973; Usoh 2010). As all the caval filter trials discussed in this review had relatively low numbers of events from moderate numbers of participants, this introduces the possibility of imprecision.

PREPIC2 was a RCT of 399 participants, followed over six months, using retrievable filters in people with VTE at high risk of recurrent PE. They did not demonstrate any advantage of routine filter insertion for the first three or six months, in those who also received anticoagulation in terms of PE, symptomatic DVT, death or bleeding (moderate-certainty evidence). There was no difference in the rates of anticoagulation between the control and filter groups. This was a well-designed RCT. See Summary of findings 1. We assessed this as moderate-certainty evidence and downgraded the certainty from
high to moderate due to some concerns over imprecision and risk of bias (low numbers of events and open-label study design).

Ho 2019 was also a well-designed RCT involving 240 participants with sustained multiple traumatic injuries who received a filter early (day three to six) or later (after day seven) versus no filter, with delayed commencement of prophylactic VTE prophylaxis, over 90 days. There was no evidence of an advantage of filter insertion to symptomatic PE, mortality, or lower limb thrombosis rates (moderate-certainty evidence). There were similar rates of anticoagulation and intermitted pneumatic compression use between the filter and control groups. Only one filter could not be retrieved percutaneously, and warranted surgical removal. See Summary of findings 2. We assessed this as moderate-certainty evidence and downgraded certainty from high to moderate due to some concerns over imprecision and risk of bias (low numbers of events and open-label study design).

We did not assess the remaining studies using GRADE criteria as they were not generally applicable to current clinical situations.

PREPIC lacked statistical power and used permanent filters that are now less frequently recommended. Fullen 1973 was of poor methodological quality and was published prior to routine prophylactic anticoagulation for post-traumatic femoral fractures, which is the current standard practice. Barginear 2012 also used permanent filters and was limited in its modest size and clinical applicability as it focussed on people with cancer and VTE. Usuh 2010 was terminated prematurely due to increased thrombosis in one filter group and compared only two of many available filters.

Potential biases in the review process

We applied no language restrictions on publications including ongoing trials. The Cochrane Vascular Information Specialist (CIS) carried out an extensive search for relevant studies. To further expand the search, we studied the reference lists of relevant articles retrieved by the above searches. Both authors identified and searched for the studies. The six included studies were clinically heterogeneous and therefore we did not pool the studies for analysis so there is limited evidence available for specific clinical situations.

Agreements and disagreements with other studies or reviews

There are reviews of filters in other circumstances such as obesity surgery but the evidence that filters may be beneficial, and without harm, is scarce (Rowland 2015). There is a paucity of RCT evidence for the effectiveness and indications for vena caval filters. Guidelines summarised in the table below are evidence-based, but the lack of RCT evidence limits the strength of their recommendations (Table 1).

The American College of Chest Physician’s Antithrombotic Therapy and Prevention of Thrombosis Guidelines, was published in 2012 (ACCP 2012), with an update in 2016 (ACCP 2016). They state that in people with VTE who can be anticoagulated, there is no indication for the use of an IVC filter; the American Heart Association (AHA 2011) and the British Society of Haematology (BSH 2006) have made similar statements. There is not enough information to make any recommendations in the subgroup who have acute PE with hypotension, who subsequently go onto to receive thrombolysis and anticoagulation. Registry data support a reduction in mortality using caval filters in this group (ACCP 2012). In people with acute PE, and a contraindication to anticoagulation, an IVC filter is recommended. In ACCP 2012, if a person has a PE, and an IVC filter is inserted, should the bleeding risk diminish, then anticoagulation should be given as if the filter was not in situ. They do not recommend continuing anticoagulation long term for a permanent filter. The ACCP guidelines (ACCP 2012; ACCP 2016), specifically do not make any recommendations regarding prophylactic indications of VCF insertion. The EAST 2002 guidelines suggest a retrievable filter be considered in people who have sustained trauma and are at high risk of VTE, including those with injuries which are a contraindication to anticoagulation, and/or injuries that result in prolonged immobility (such as significant head injuries, spinal cord injury with resultant paraplegia or quadriplegia, complex pelvic and/or long bone(s) fractures), but these have not been updated since the publication of Ho 2019.

Authors’ conclusions

Implications for practice

Two of the six identified studies were relevant for current clinical settings. One showed no evidence of a difference with retrievable filters in acute PE for the outcomes of PE, death, symptomatic DVT and bleeding during the initial three months in people who could receive anticoagulation (moderate-certainty evidence). The other study did not show any evidence of a difference after prophylactic filter insertion in people who sustained multiple traumatic injuries with respect to symptomatic PE, mortality rates, or lower limb venous thrombosis (moderate-certainty evidence). No firm conclusions regarding filter efficacy in the prevention of PE can be drawn from the remaining four RCTs identified in this review.

With the paucity of evidence for groups of people for whom filters are potentially beneficial and for the use of retrievable filters, the American College of Chest Physician Guidelines (ACCP 2012) suggest the current accepted indication for filters is a contraindication to anticoagulation. Clinical judgement is required for other indications in which filters may be considered, such as for patients with VTE and diminished cardiopulmonary reserve, those undergoing high-risk surgery, or those who receive thrombolysis for a proximal DVT. It would appear to be prudent to scan the lower limbs to confirm the presence of residual thrombus before contemplating filter insertion.

Implications for research

Information regarding the indications is lacking, and short- and long-term complications of permanent and retrievable filters is incomplete (Brown 2017; Deso 2016). Large RCTs are desirable in groups of people who have failed, or have contraindications to anticoagulation, to confirm the efficacy of caval filters in this group; similarly, in people who have cancer and concurrent VTE, and in those with upper limb thrombosis and superior vena caval filters. Large RCTs to compare the various retrievable filter brands/types would provide useful information about their efficacy and complication rates. However, relatively few filters are inserted and so the time to enroll sufficient numbers is considerable - recruitment in PREPIC and PREPIC2 for 400 participants took four and six years respectively; Ho 2019 recruited 240 people over 2.5 years. Registry data may provide supplemental information. Outcomes should ideally include rates of PE and DVT, mortality, post-thrombotic syndrome and its effects on quality of life; filter-
related complications: mortality from filter insertion, clinical filter embolism and perforation, and caval thrombosis. The duration of these trials should be at least two years to provide an indication of long-term complication rates.

ACKNOWLEDGEMENTS

Thanks to Cochrane Vascular for assisting with the search for relevant articles; Carmel Williams at the Butfield library at the NWRH and the University of Queensland Library for obtaining articles; and Dr Harry Bartlett (QUT) for statistical advice and input. The review authors would like to thank Rodney Hughes for his involvement in previous versions of the review. The review authors and the Cochrane Vascular Editorial base thank the peer referees for their comments.
References to studies included in this review

Barginear 2012 (published data only)

Ho 2019 (published data only)


PREPIC (published data only)


PREPIC2 (published data only)


Usoh 2010 (published data only)

References to studies excluded from this review

Bocharov 2011 (published data only)

Brasel 1997 (published data only)

Gosin 1997 (published data only)
Vena caval filters for the prevention of pulmonary embolism (Review)

References to ongoing studies

ACTRN12612001071819 (published data only)
ACTRN12612001071819. A randomised study to compare the technical difficulty of retrieval between the Bard G2X and the Cook Celect versus Denali filter. clinicaltrials.gov/ct2/show/NCT03987321 (first posted 17 June 2019).

ChiCTR1900023485 (published data only)

NCT00588757 (published data only)

NCT03070834 (published data only)

NCT03691753 (published data only)

NCT03987321 (published data only)

References

Khangarinia 1995 (published data only)

Midy 1994 (published data only)

NCT00423683 (published data only)

NCT02201277 (published data only)

Pan 2019 (published data only)

Rajasekhar 2011 (published data only)

Rodriguez 1996 (published data only)

Rogers 1997 (published data only)

Rosenthal 1994 (published data only)

Rosner 2004 (published data only)

Sharifi 2012 (published data only)

Stavropoulos 2016 (published data only)

Webb 1992 (published data only)

References to ongoing studies

ACTRN12612001071819 (published data only)
ACTRN12612001071819. A randomised study to compare the technical difficulty of retrieval between the Bard G2X and the Cook Celect Vena Cava Filter systems in patients at high risk for pulmonary embolism. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336779 (first posted 8 October 2012).

ChiCTR1900023485 (published data only)

NCT00588757 (published data only)

NCT03070834 (published data only)

NCT03691753 (published data only)

NCT03987321 (published data only)
Additional references

ACCP 2012

ACCP 2016

ACR-SIR Practice Parameter 2014

AHA 2011

Brown 2017

BSH 2006

Carter 2020

Chiu 2017

Deso 2016

Douketis 1998

EAST 2002

ESC 2014

Gomes 2003
Gomes MPV, Kaplan KL, Deitcher SR. Patients with inferior vena cava filters should receive chronic thromboprophylaxis. Medical Clinics of North America 2003;87:1189-203.

GRADEpro GDT [Computer program]

Greenspan 1982

Guyatt 2008

Hann 2005

Higgins 2011

Imberti 2005
Jadad 1996


Kalva 2008


Karmy-Jones 2007


Kinney 2003


Lefebvre 2011


Lessne 2015


Norris 1985


Owens 2010


PIOPED


Radomski 1987


Rajeshekar 2013


Rowland 2015


Schulman 2005


Sutherland 2017


Tapson 2017


References to other published versions of this review

Young 2006


Young 2007a


Young 2007b


Young 2010


* Indicates the major publication for the study
### Characteristics of included studies [ordered by study ID]

**Barginear 2012**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: randomised single-centre study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Country: United States</td>
</tr>
<tr>
<td></td>
<td>Follow-up: 3 years</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th>64 people who had cancer and VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age range: 51-81 yrs</td>
</tr>
<tr>
<td></td>
<td>40 of the 64 participants were female</td>
</tr>
<tr>
<td></td>
<td>Inclusion criteria: age &gt; 18 yrs, with definite diagnosis of cancer, diagnosed with acute DVT or PE, who were receiving anticoagulation</td>
</tr>
<tr>
<td></td>
<td>Exclusion criteria: previous filter in situ, renal impairment with creatinine clearance &lt; 30 mL/min, indication for thrombolysis, allergy to iodine, pregnancy, active bleeding requiring transfusion, platelet count &lt; 50, hereditary thrombophilia, intracranial bleeding, brain metastases secondary to melanoma/choriocarcinoma/renal cell carcinoma/or medullary thyroid carcinoma</td>
</tr>
</tbody>
</table>

| Interventions | Vena Tech (permanent) filters were inserted within 3 days of randomisation |

| Outcomes | Survival, recurrent PE, complications with filter insertion |

| Funding | This study was supported in part by a grant from GlaxoSmithKline (Supportive Care in Cancer 20, 2865 - 2872 (2012)). |

| Declarations of interest | There were no financial disclosures from any authors (Supportive Care in Cancer 20, 2865 - 2872 (2012)). |

| Notes | The number of participants was small, and it was done at one centre. |
|       | The anticoagulant fondaparinux was given to both the intervention (filter) and control arm. |

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated permuted block design</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated permuted block design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) Mortality</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
</tbody>
</table>
### Barginear 2012 (Continued)

<table>
<thead>
<tr>
<th>PE</th>
<th>Blinding of outcome assessment (detection bias) Mortality</th>
<th>Unclear risk</th>
<th>Not stated if radiologists blinded to participants filter status; all 'events' were evaluated by an Independent Safety Monitoring Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE</td>
<td>Blinding of outcome assessment (detection bias) PE</td>
<td>Unclear risk</td>
<td>Not stated if radiologists blinded to participants filter status; all 'events' were evaluated by an Independent Safety Monitoring Board</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Mortality</td>
<td>Low risk</td>
<td>Follow-up was adequate. No loss of data</td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) PE</td>
<td>Low risk</td>
<td>Follow-up was adequate. No loss of data</td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes were reported</td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
<td></td>
</tr>
</tbody>
</table>

### Fullen 1973

**Study characteristics**

- **Methods**
  - Study design: a single-centre study
  - Country: United States
  - Follow-up was an average of 33-34 days

- **Participants**
  - Number: 129 participants with proximal femoral fractures
  - Age: average age 69 and 67 years (filter and control group, respectively)
  - Sex: gender distribution not stated
  - Inclusion criteria: proximal femoral fractures were invited to participate in the study.
  - Exclusion criteria: refusal to participate in the trial

- **Interventions**
  - Treatment: permanent caval filter
  - Control: no filter

- **Outcomes**
  - Primary outcomes:
    1. Mortality
    2. PE
  - Secondary outcomes:
    1. Complications from filter insertion
  - Outcomes assessed when clinically indicated and at discharge
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>Randomisation based on odd or even hospital numbers and a higher rate of atherosclerotic heart disease and cardiac failure was noted in the filter group</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Participation in filter group based on consent</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) Mortality</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) PE</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Mortality</td>
<td>Unclear risk</td>
<td>Blinding of outcome assessors not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) PE</td>
<td>Unclear risk</td>
<td>Blinding of outcome assessors not stated. Use of chest radiography and V/Q scan in diagnosis of PE is inaccurate. Not stated whether all participants had routine imaging, or only when clinically indicated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Mortality</td>
<td>Low risk</td>
<td>Cause of death and numbers reported. Follow-up complete as in-hospital population</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) PE</td>
<td>Low risk</td>
<td>Definite, probable and possible pulmonary embolism rates reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Protocol brief. Mortality, PE and filter complication outcomes documented. Rates of DVT not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>The imaging technology available at the time may have under-reported the rates of pulmonary embolism.</td>
</tr>
</tbody>
</table>

### Study characteristics

#### Ho 2019
methods

study design: multicentre, randomised open-label study

country: Australia, majority of participants based in one major metropolitan city in Australia

follow-up: 90 days

participants

number: 240 people who sustained multiple traumatic injuries

age: 24-57 years

gender: male 81%

inclusion criteria:

1. age > 18 years

2. injury severity score of 15 or more

3. contraindication to anticoagulation within 72 hours after injury

exclusion criteria:

1. severe head or traumatic injury such that death was expected within 48-72 hours

2. the treating clinicians judged that it was safe to commence prophylactic anticoagulation within 72 hours of injury

3. people who already had PE on CT pulmonary angiography at admission

4. people who were already on systemic anticoagulation for a pre-existing medical comorbidity (for example, atrial fibrillation, or previous DVT/PE)

5. pregnancy

6. there would be a delay for IVC filter insertion for > 72 hours from admission

7. age < 18 years

Interventions

Early (days 3-6) vs delayed (on, or after day 7) retrievable filter insertion

Outcomes

Primary:

1. Composite of a) symptomatic PE or b) mortality

2. Cost-effectiveness of using VCFs to prevent PE after major trauma (inclusive of costs of the VCF, number of radiological scans, length of ICU and hospital stay, procedure and medications required to treat PE and/or complications from the filter itself

Secondary:

1. Symptomatic fatal and non-fatal PE between day 8 and 90 in people who could not receive prophylactic anticoagulation within 7 days of injury

2. Filter-related complications, including DVT within 90 days as detected by a screening ultrasound at 2 weeks; the latter was reported as a post hoc secondary outcome.

3. All cause mortality

4. Bleeding (note "major bleeding" was not designated as per the ISTH (Schulman 2005). In this trial, it was defined as bleeding that contributed to death; occurred at a critical site (e.g. intracranial, intraspinal, epidural, or lung haemorrhage); led to transfusion of 2 more units of red cells, platelets, or fresh frozen plasma; or was associated with a decrease in the haemoglobin level of more than 2 grams per decilitre within any 24-hour period after injury. Non-major bleeding was defined as bleeding that led to new medical interventions (e.g. gastrointestinal endoscopy or local or systemic drugs to control bleeding. Minor bleeding that did not result in any medical intervention was not reported).
A cost-effectiveness analysis was also one of the endpoints; these results will be reported in a subsequent publication of the study.

### Funding

Supported by the Medical Research Foundation of Royal Perth Hospital and the Western Australia Department of Health. The funders provided financial support to employ the research coordinators and for the cost of ultrasonography for this trial. Dr Ho was funded by the Western Australia Department of Health and the Raine Medical Research Foundation through the Raine Clinical Research Fellowship to initiate and conduct this trial. No financial or nonfinancial (including in-kind) support has been received from any commercial entities.

### Declarations of interest

Dr Ho reports serving on an advisory board for Medtronic and serving as an advisor for Cardinal Health; Dr Lipman reported that he received advisory board fees, paid to his institution, from Bayer and MSD, lecture fees from Pfizer South Africa and MSD South Africa, and honoraria from Pfizer. No other potential conflict of interest relevant to this article was reported.

### Notes

The rates and commencement of prophylactic anticoagulation were recorded, as was the utility of intermittent pneumatic compression.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation was done via permuted-block scheme, stratified according to the trial centre.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated permuted-block design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) Mortality</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) PE</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Mortality</td>
<td>Unclear risk</td>
<td>Blinding of assessors not stated; the coronial investigators would not have been blinded to the filter status of the participant</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) PE</td>
<td>Unclear risk</td>
<td>Blinding of the radiology outcome assessors not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Mortality</td>
<td>Low risk</td>
<td>Only one person lost to follow-up</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) PE</td>
<td>Low risk</td>
<td>Only one person lost to follow-up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
</tr>
</tbody>
</table>
**Study characteristics**

**Methods**
- Study design: multicentre study; randomised controlled open-label trial using a 2 x 2 factorial design
- Country: France
- Follow-up: 8 yrs
- Intention-to-treat analysis

**Participants**
- Number: 400 participants
- Age: 73 +/- 11
- Sex: 64% were male
- Inclusion criteria: age > 18 with documented proximal DVT or PE, and considered high risk for recurrent PE
- Exclusion criteria:
  1. previous filter
  2. contraindication or failure of anticoagulation
  3. curative anticoagulation > 48 hours duration
  4. indication for thrombolysis
  5. short life expectancy
  6. allergy to iodine
  7. hereditary thrombophilia
  8. severe renal or hepatic failure
  9. pregnancy
  10. likely non-compliance

**Interventions**
- (Permanent) caval filter vs no filter
- LMWH vs unfractionated heparin

**Outcomes**
- Primary outcomes
  1. PE
  2. Mortality
  3. DVT
- Secondary outcomes
  1. Bleeding
  2. PTS
  3. Filter-related complications
- Outcomes assessed at 12 days, two years, eight years

**Funding**
- This study was supported by grants from Ministère Français de la Santé (PHRC), Paris, France, and from Fondation de l’Avenir.

**Declarations of interest**
- Jean-Yves Darmon and Yves Cadroy (MediBridge Clinical Research, Vélizy, France) provided editorial assistance. No other disclosures were reported.

**Notes**
- Study had low power.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation was based on a centralised computer system.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Centralised computer telephone system</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) Mortality</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) PE</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Mortality</td>
<td>Low risk</td>
<td>An independent adjudication committee who assessed all radiological and clinical outcomes was blinded to the treatment status of the participants.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) PE</td>
<td>Low risk</td>
<td>An independent adjudication committee who assessed all radiological and clinical outcomes was blinded to the treatment status of the participants.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Mortality</td>
<td>Low risk</td>
<td>Negligible losses to follow-up (only 4 of 400 participants). No missing outcome data. Causes of death reported. Mortality reported at 12 days, two years and eight years</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) PE</td>
<td>Low risk</td>
<td>No missing outcome data. PE reported at 12 days, two years and eight years</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes were reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
</tr>
</tbody>
</table>

### Study characteristics

**Methods**

- Study design: prospective, multicentre, open-label
- Country: France
- Follow-up: 6 months duration

**Participants**

- People (399) at high risk of recurrent PE, i.e. DVT of the lower limb with any of the following:
  - age > 75
  - presence of right ventricular dysfunction
**PREPIC2 (Continued)**

- active cancer
- bilateral DVT and/or ilio-caval thrombosis
- cardiorespiratory insufficiency

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Retrievable (ALN Implants Chirurgicaux Ghisonaccia, France) filter vs no filter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Primary outcome:</td>
</tr>
<tr>
<td></td>
<td>1. recurrent PE at 3 months</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes:</td>
</tr>
<tr>
<td></td>
<td>1. DVT at 3 months</td>
</tr>
<tr>
<td></td>
<td>2. VTE at 6 months</td>
</tr>
<tr>
<td></td>
<td>3. major bleeding</td>
</tr>
<tr>
<td></td>
<td>4. mortality at 3 months</td>
</tr>
<tr>
<td></td>
<td>5. mortality at 6 months</td>
</tr>
<tr>
<td></td>
<td>6. filter-related complications</td>
</tr>
</tbody>
</table>

**Funding**
The study was supported by grants from the Programme Hospitalier de Recherche Clinique (French Department of Health), Fondation de l’Avenir and Fondation de France. Filters were packaged and provided free of charge by ALN Implants Chirurgicaux. The study sponsor was the University Hospital of Saint-Etienne. An academic steering committee assumed overall responsibility for all these steps. An independent data and safety monitoring committee periodically reviewed the main safety outcomes.

The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. An academic steering committee assumed overall responsibility for all these steps.

**Declarations of interest**

Dr Mismetti reports receiving research grants from Bayer and fees for board memberships from Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, for lectures from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, and Sanofi-aventis, and for development of educational presentations from Bayer, Bristol-Myers Squibb/Pfizer. Dr Laporte reports receiving fees for board memberships or consultancy from Bayer, Ferring, Leo Pharma, Pierre Fabre Santé, and Sanofi-aventis. Dr Pellerin reports receiving consultant fees from Perouse Medicale, Siemens Heath care, BTG International, Covidien, Merit Medical, b-Braun, and Boston Scientific. Dr Couturaud reports receiving research grant support from Bristol-Myers Squibb and Daiichi Sankyo. Dr Elias reports receiving research grant support and fees for board membership and consultancy activities from Bayer and Daiichi Sankyo. Dr Menneveau reports receiving research grant support from Boehringer Ingelheim and Bayer, and fees for consultancy from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb. Dr Roy reports receiving research grant support from Bayer and Sanofi-aventis, and fees for board membership and consultancy activities for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, and Daiichi Sankyo. Dr Sanchez reports receiving research grant support from Portola Pharmaceuticals, and Daiichi Sankyo, and fees or nonfinancial support for consultancy activities from Actelion, Boehringer Ingelheim, GlaaxoSmithKline, and Chiesi. Dr Schmidt reports receiving fees for board membership from Bayer and Daiichi Sankyo and for symposia from Bayer. Dr Seinturier reports receiving fees for symposia from Bayer and Actelion and receiving travel support from Bayer, Pfizer, Leo Pharma, Actelion, ABS-Bolton Medical, and Sanofi-aventis. Dr Sevestre reports receiving fees for consultancy from Bayer, Leo Pharma, and GlaaxoSmithKline. Dr Lacroix reports uncompensated board membership and consultancy activities for Bayer and Sanofi-aventis, and receiving travel support from Bayer and AstraZeneca. Dr Leizorovicz reports receiving research grant support from Bristol-Myers Squibb, GlaaxoSmithKline, Portola Pharmaceuticals, and Sanofi-aventis, and fees for board memberships or consultancy from Bayer, Boehringer Ingelheim, and Sanofi-aventis. Dr Décousus reports receiving personal fees from ASPEN, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, and Bayer and grant funding from Bayer and Daiichi Sankyo. Dr Meyer reports receiving research grant support from Bayer, Boehringer Ingelheim, Leo Pharma, and Sanofi-
We thank Jean-Yves Darmon, MD (MediBridge SA, Velizy, France), for critically reviewing the manuscript during its development and providing editorial assistance funded by the Programme Hospitalier de Recherche Clinique. No member of the PREPIC2 Study Group received compensation for his or her role in the study.

No other disclosures were reported.'

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Centralised randomisation, computer-generated randomly permuted blocks</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Central voice-activated system, in randomly permuted blocks</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>PE</td>
<td>High risk</td>
<td>Open-label study design</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>The evaluation was blind, performed by a central adjudication committee.</td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>The evaluation was blind, performed by a central adjudication committee.</td>
</tr>
<tr>
<td>PE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Only 2 people lost in follow-up</td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Only 2 people lost in follow-up</td>
</tr>
<tr>
<td>PE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary and secondary outcomes were reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
</tr>
</tbody>
</table>
Study characteristics

Methods
Study design: single-centre study
Country: US
Follow-up: planned for 2 yrs but study terminated prematurely because of interim results

Participants
156 people with lower limb DVT, or at high risk of PE
Age range: 24-101 yrs
Inclusion criteria:
• contraindication to anticoagulation with DVT/PE
• failed anticoagulation with DVT/PE
• trauma patient at high risk for DVT/PE
• high-risk procedure for thromboembolism with history of VTE
Exclusion criteria:
• age < 18 yrs
• pre-existing filter
• uncontrollable coagulopathy
• vena cava diameter > 30 mm
• hypersensitivity to nickel, chromium, stainless steel
• pregnancy
• non-femoral access for IVC filter placement
• supra-renal IVC filter placement

Interventions
IVC filter: Greenfield (permanent) or TrapEase (permanent)

Outcomes
Mortality
Recurrent PE
Iliac or IVC thrombosis

Funding
Not stated

Declarations of interest
None declared

Notes
The study group was randomised to one of two filters. The paper stated there was a non-randomised group who also received filters based on the proceduralists choice, or filter availability (3 received a different filter from the original options of a Greenfield or TrapEase filter; these people received an Optease filter). This non-randomised group was not part of the study's analysis or conclusions, as they were not followed up. However, it is noted that 1/232 people with the Greenfield filter in situ, 2/114 people with the TrapEase filter in situ, and 0/3 people with the Optease filter in situ had IVCT/IVT

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>A nurse or the patient randomly picked a prelabelled index card from an envelope.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>‘prelabelled card in an envelope’ - not stated if opaque envelope, randomly ordered envelopes, card was concealed within a separate envelope</td>
</tr>
</tbody>
</table>
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bocharov 2011</td>
<td>Not a randomised controlled trial</td>
</tr>
<tr>
<td>Brasel 1997</td>
<td>Cost-effectiveness analysis</td>
</tr>
<tr>
<td>Gosin 1997</td>
<td>Prospective interventional cohort with historical control; selected high-risk people received filters; no data on baseline characteristics of the interventional cohort and the control group</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Khansarinia 1995</td>
<td>Prospective interventional cohort with historical control</td>
</tr>
<tr>
<td>Midy 1994</td>
<td>Case series</td>
</tr>
<tr>
<td>NCT00423683</td>
<td>Study terminated early</td>
</tr>
<tr>
<td>NCT02201277</td>
<td>Study terminated early</td>
</tr>
<tr>
<td>Pan 2019</td>
<td>A retrospective cohort analysis</td>
</tr>
<tr>
<td>Rajasekhar 2011</td>
<td>Feasability study of vena cava insertion into people with trauma</td>
</tr>
<tr>
<td>Rodriguez 1996</td>
<td>Prospective interventional cohort with historical control</td>
</tr>
<tr>
<td>Rogers 1997</td>
<td>Prospective interventional cohort with historical control; selected high-risk people received filters; interventional and cohort groups unmatched according to baseline characteristics</td>
</tr>
<tr>
<td>Rosenthal 1994</td>
<td>Case series</td>
</tr>
<tr>
<td>Rosner 2004</td>
<td>Prospective interventional cohort with historical control</td>
</tr>
<tr>
<td>Sharifi 2012</td>
<td>Participants randomised filters as an adjunct to percutaneous endovascular techniques for the treatment of lower limb DVT</td>
</tr>
<tr>
<td>Stavropoulos 2016</td>
<td>A prospective single-arm cohort analysis</td>
</tr>
<tr>
<td>Webb 1992</td>
<td>Selected high-risk patients received filters; no data on baseline characteristics of interventional and control groups; people received concurrent DVT prophylaxis</td>
</tr>
</tbody>
</table>

DVT: deep vein thrombosis

Characteristics of ongoing studies [ordered by study ID]

ACTRN12612001071819

Study name: A randomised study to compare the technical difficulty of retrieval between the Bard G2X and the Cook Celect vena cava filter systems in patients at high risk for pulmonary embolism

Methods: Prospective randomised open-label

Participants:

1. Any patient considered at high risk for pulmonary embolism and is under consideration for placement of a short-term VCF. The patient should have at least one of the following 7 indications:
   a. Patients with evidence of PE embolus or IVC, iliac, or femoral-popliteal DVT and a contraindication, complication, or failure of anticoagulation
   b. Massive PE with residual DVT in a patient at risk for further PE
   c. Free-floating iliofemoral or IVC thrombus
   d. Severe cardiopulmonary disease and DVT (e.g. cor pulmonale with pulmonary hypertension)
   e. Poor compliance with anticoagulant medications
   f. Severe trauma without documented PE or DVT in patient with a closed head injury, spinal cord injury, or multiple long bone or pelvic fractures
   g. High-risk patients (e.g. immobilised, intensive care patients, prophylactic pre-operative placement in patients with multiple risk factors for VTE)
2. Patient must have patent internal jugular vein
3. Age: greater than or equal to 18 years
4. Patient or person responsible must have signed the informed consent form

Age: 18-80 yrs
Gender: both males and females

Key exclusion criteria:
1. Age < 18 yrs
2. Pregnancy
3. Uncontrollable coagulopathy
4. Vena cava diameter over 30 mm, measured by vena cava sizing catheters
5. Vena cava diameter less than 15 mm, measured by vena cava sizing catheters
6. Contrast allergy that cannot be adequately pre-mediated
7. Simultaneously participating in another investigative drug or device trial, or have a previous IVC filter

Interventions

Comparator/control treatment:
Comparing the retrievability of 2 TGA-approved IVC filters
One group will be randomised to receiving the Cook Filter and the other group will be randomised to the Bard filter. We will then determine which of the two filters is easier to remove.

Outcomes

Primary outcome: technical difficulty of retrieval will be assessed by the radiologist using a 5-point numerical scale. The time point of the outcome, retrieving the filter, will vary based on the clinical need of the patient. The filter will be removed when the patient is no longer at risk of developing a PE.

Secondary outcome: composite serious adverse events
Examples of expected adverse events include:
10 in 100 chance of haemorrhage (bleeding) and perforation (tearing) of the blood vessel
4 in 100 chance of PE (blood clot in the lung)
10 in 100 chance of occlusion (blockage) of the blood vessel
Less than 16 in 100 chance of significant filter migration (shifting in position)
10 in 100 chance of fracture of the filter
< 1 in 100 chance of procedure-related death

Time points: procedure; 1, 3, 6 12 months; time of retrieval

Starting date
15/04/2010

Contact information
Name: Helen Kavnoudias
Address: Radiology Department
The Alfred Hospital
Commercial Road
Melbourne, Vic 3004 Country Australia

Notes

ChiCTR1900023485

Study name
Prospective, multicentre, randomised controlled trial to assess the safety and performance of the Ballet vena cava filter system for the prevention of pulmonary embolism

Methods
Randomised parallel group
ChiCTR1900023485 (Continued)

### Participants
144 participants, age > 18 years

**Inclusion criteria:**
1. People who agreed to participate with voluntary written consent
2. People who were at high risk of PE meeting one of the following:
   a. People with PE or inferior or femoral condyle vein thrombosis and:
      i. contraindication to anticoagulation or;
      ii. complications from anticoagulation such as bleeding, or;
      iii. recurrent PE despite anticoagulation.
   b. There are free thrombi or massive thrombi in the iliac crest, femoral vein or IVC
   c. People with thrombophilia and recurrent PE
   d. People with acute lower limb DVT requiring catheter thrombolysis and thrombectomy

**Exclusion criteria:**
1. Pregnancy or lactation
2. Participant is actively involved in another drug or medical device clinical trial
3. People with chronic IVC thrombosis or severe IVC stenosis
4. The person has massive, life-threatening PE
5. Allergy to contrast and anaesthetics
6. Other situations in which the investigator determines it is not appropriate for endovascular treatment

### Interventions
Ballet vena cava filter vs a Lifetech Medical Technology VCF

### Outcomes
**Primary:** Incidence of PE with VCF in situ

**Secondary:**
1. Successful filter insertion rate
2. Successful filter retrieval rate
3. Incidence of PE within 30 days of VCF retrieval
4. Incidence of adverse events
5. Filter-related complications - caval obstruction, filter breakage, IVC perforation, filter tilt (> 15 degrees) and displacement (> 2 cm)

### Starting date
Not stated

### Contact information
Name: Sun Yan
Address: Hangzhou Weiquang Medical Technology Co, Ltd, Room 318, Building 2, Wantan Science Park, 88 Jiangling Road, Binjiang District, Hangzhou, Zhejiang, China

### Notes

---

**NCT00588757**

**Study name**
Complications between two optional IVC filters regarding ease of use, complications and outcome

**Methods**
Randomised parallel group assignment

**Participants**
100 participants, age > 18 years

**Inclusion criteria:** all people referred for filter insertion
<table>
<thead>
<tr>
<th>Study name</th>
<th>Retrieval Inferior vena caval filter for primary PE prophylaxis in at-risk Trauma patients (RIPT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised parallel group assignment</td>
</tr>
<tr>
<td>Participants</td>
<td>42 people, age &gt; 18 years with trauma who are:</td>
</tr>
<tr>
<td></td>
<td>1. deemed unable to receive medical VTE prophylaxis within 72 hours post-injury based on traumaologists’ suspicion of increased bleeding risk, per-spinal cord bleeding risk, or need for multiple surgical interventions; and</td>
</tr>
<tr>
<td></td>
<td>2. have at least one of the following high-risk VTE injuries as per the EAST Guidelines:</td>
</tr>
<tr>
<td></td>
<td>a. severe closed head injury (GCS 8 or less upon presentation)</td>
</tr>
<tr>
<td></td>
<td>b. incomplete spinal cord injury with para- or quadriplegia</td>
</tr>
<tr>
<td></td>
<td>c. complex pelvic fracture with associated long bone fracture(s)</td>
</tr>
<tr>
<td></td>
<td>d. multiple long bone fractures.</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. people who were not expected to survive for at least 72 hours post-trauma</td>
</tr>
<tr>
<td></td>
<td>2. people with known uncorrectable coagulopathy</td>
</tr>
<tr>
<td></td>
<td>3. people known to be unable to receive a retrievable VCF as part of this trial (for anatomical reasons or standard contraindication for device insertion)</td>
</tr>
<tr>
<td></td>
<td>4. known active VTE</td>
</tr>
<tr>
<td></td>
<td>5. pregnancy</td>
</tr>
<tr>
<td>Interventions</td>
<td>Cook ‘Celect’ Filter and pharmacologic anticoagulation commenced when safe, vs no filter and pharmacologic anticoagulation when safe</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: time left unprotected to PE</td>
</tr>
<tr>
<td></td>
<td>Secondary:</td>
</tr>
<tr>
<td></td>
<td>1. Symptomatic VTE</td>
</tr>
<tr>
<td></td>
<td>2. Mortality</td>
</tr>
<tr>
<td></td>
<td>3. Time to filter insertion</td>
</tr>
<tr>
<td></td>
<td>4. Time and rates to/of filter retrieval</td>
</tr>
<tr>
<td></td>
<td>5. Rates of worsening intracranial bleed</td>
</tr>
<tr>
<td>Starting date</td>
<td>March 2017</td>
</tr>
<tr>
<td>Contact information</td>
<td>Name: Ian Ball</td>
</tr>
</tbody>
</table>
Study name: Safety and efficacy of Fitaya vena cava filter for deep vein thrombosis: a multicentre, randomized controlled trial

Methods: Randomised parallel assignment

Participants: 186 participants, age > 18 years

Inclusion criteria:
1. People who agreed to participate with voluntary written consent, and agreement for follow-up
2. People with inferior DVT (IVC, iliac, femoral or popliteal DVT) or PE and concomitant with one or more of the following situations:
   a. contraindication to pharmacological anticoagulation
   b. bleeding complications during anticoagulation therapy
   c. recurrent PE despite adequate anticoagulation therapy
   d. unable to achieve adequate anticoagulation
   e. PE with coexistent inferior DVT
   f. free thrombosis or large amounts of thrombosis are found in the iliac, femoral, popliteal, or inferior vena cava
   g. people who have acute risk factors of DVT and PE needing to undergo abdominal, pelvic or lower limb surgery simultaneously
   h. people with acute DVT, prior to catheter-directed thrombolysis (CDT), percutaneous mechanical thrombectomy (PMT), or surgical thrombectomy
3. The investigator determined the participant had appropriate femoral or jugular access for filter insertion
4. The diameter of the IVC for proposed filter implantation is between 18 mm and 29 mm

Exclusion criteria:
1. People with a previous IVC filter
2. Thrombosis of the femoral or jugular vein preventing filter insertion
3. Permanent filter indicated
4. Severe spinal deformity affecting either filter insertion or retrieval
5. Renal vein thrombosis, or IVC thrombosis involving the renal vein
6. Congenital malformation of the IVC
7. Uncontrolled sepsis or severe infection
8. Active malignancy, with metastatic disease
9. Allergy to filter components
10. People who have contraindication to x-rays
11. Liver or renal dysfunction - defined as transaminases 2.5 times the upper limit of normal (ULN), or serum creatinine two times higher the ULN
12. Pre-existing abnormal coagulation - defined as activated partial thrombin time (APTT) 10 seconds above ULN
13. People whose life expectancy was less than 12 months
14. People who had severe heart or lung disease
15. Pregnant or lactating women, or women trying to conceive
### NCT03691753 (Continued)

16. People who were actively participating in other clinical trials involving other drugs or medical devices, who did not withdraw within the first 3 months of the screening period in this trial.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Fitaya VCF vs Aegisy VCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Primary:</td>
</tr>
<tr>
<td></td>
<td>1. The insertion rate and resultant filter positioning</td>
</tr>
<tr>
<td></td>
<td>2. Rate of symptomatic PE at 6 months, as determined by Computed Tomography Pulmonary Angiography (CTPA)</td>
</tr>
<tr>
<td></td>
<td>3. Filter-related complications such as IVC penetration or rupture, filter displacement, filter thrombosis, filter-related mortality</td>
</tr>
<tr>
<td>Starting date</td>
<td>Oct 2018</td>
</tr>
<tr>
<td>Contact information</td>
<td>Name: Ying Xia</td>
</tr>
</tbody>
</table>

### NCT03987321

| Study name | Retrievability and incidence of complex retrieval in Celect vs Denali Filter: a prospective, randomized comparative study |
| Methods    | Randomised parallel group assignment |
| Participants | 174 participants, age > 18 years with either: |
|            | 1. DVT and/or PE, who are commenced on anticoagulation, or |
|            | 2. prior to mechanical thrombectomy for DVT, or |
|            | 3. prophylactic prior to trauma or major surgery. |
|            | People who were septic or needed a permanent filter were excluded. |
| Interventions | Denali or Celect Filter |
| Outcomes   | Primary: incidence of complicated filter retrieval at 2 months |
|           | Secondary: |
|           | 1. incidence of penetration at 2 months |
|           | 2. tilt angle at 2 months |
|           | 3. filter migration/fracture at 2 months |
|           | 4. signs of inferior vena caval occlusion/stenosis at 2 months |
| Starting date | July 2019 |
| Contact information | Name: Man-Deuk Kim |
|                   | Address: Department of Radiology, Severance Hospital, Yonsei College of Medicine, Seoul, Republic of Korea |

Notes

APTT: activated partial thrombin time  
CDT: catheter-directed thrombolysis
CT: computed tomography  
CTPA: computed tomography pulmonary angiography  
DVT: deep vein thrombosis  
EAST: Eastern Association for the Surgery of Trauma  
GCS: Glasgow Coma Scale  
IVC: inferior vena caval  
LMWH: low molecular weight heparin  
MRI: magnetic resonance imaging scan  
PE: pulmonary embolism  
PI: principal investigator  
PMT: percutaneous mechanical thrombectomy  
TGA: Therapeutic Goods Administration (Department of Health, Australia)  
UCSF: University of California San Francisco  
UFH: unfractionated heparin  
ULN: upper limit of normal  
VCF: vena caval filter  
vs: versus  
VTE: venous thromboembolism  
ys: years

**DATA AND ANALYSES**

**Comparison 1. Anticoagulation +/- VCF in people at high risk of recurrent PE**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 PE</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.1.1 3 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.1.2 6 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.2 Mortality</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.2.1 3 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.2.2 6 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.3 Lower limb thrombosis</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.3.1 3 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.3.2 6 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.4 Major bleeding</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.4.1 3 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.4.2 6 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 1: PE

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>1.1.1 3 months PREPIC2</td>
<td>6</td>
<td>200</td>
<td>3</td>
<td>199</td>
</tr>
<tr>
<td>1.1.2 6 months PREPIC2</td>
<td>7</td>
<td>200</td>
<td>4</td>
<td>199</td>
</tr>
</tbody>
</table>

### Analysis 1.2. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 2: Mortality

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>1.2.1 3 months PREPIC2</td>
<td>15</td>
<td>200</td>
<td>12</td>
<td>199</td>
</tr>
<tr>
<td>1.2.2 6 months PREPIC2</td>
<td>21</td>
<td>200</td>
<td>15</td>
<td>199</td>
</tr>
</tbody>
</table>

### Analysis 1.3. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 3: Lower limb thrombosis

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>1.3.1 3 months PREPIC2</td>
<td>1</td>
<td>200</td>
<td>1</td>
<td>199</td>
</tr>
<tr>
<td>1.3.2 6 months PREPIC2</td>
<td>1</td>
<td>200</td>
<td>2</td>
<td>199</td>
</tr>
</tbody>
</table>
Analysis 1.4. Comparison 1: Anticoagulation +/- VCF in people at high risk of recurrent PE, Outcome 4: Major bleeding

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
</tr>
<tr>
<td>1.4.1 3 months PREPIC2</td>
<td>8</td>
<td>200</td>
<td>10</td>
</tr>
<tr>
<td>1.4.2 6 months PREPIC2</td>
<td>13</td>
<td>200</td>
<td>15</td>
</tr>
</tbody>
</table>

Comparison 2. Anticoagulation +/- VCF in people after multiple trauma

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 PE</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.2 Mortality</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.3 Lower limb thrombosis</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.3.1 All</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.3.2 Unilateral</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.3.3 Bilateral</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.4 Major bleeding</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.5 Non major bleeding</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

Analysis 2.1. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 1: PE

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
</tr>
<tr>
<td>Ho 2019</td>
<td>0</td>
<td>46</td>
<td>5</td>
</tr>
</tbody>
</table>
## Analysis 2.2. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 2: Mortality

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Ho 2019</td>
<td>16</td>
<td>122</td>
<td>11</td>
<td>118</td>
</tr>
</tbody>
</table>

Footnotes

(1) Some participants had more than one episode of thrombosis

## Analysis 2.3. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 3: Lower limb thrombosis

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>2.3.1 All</td>
<td>14</td>
<td>122</td>
<td>12</td>
<td>118</td>
</tr>
<tr>
<td>Ho 2019 (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3.2 Unilateral</td>
<td>11</td>
<td>122</td>
<td>6</td>
<td>118</td>
</tr>
<tr>
<td>Ho 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3.3 Bilateral</td>
<td>4</td>
<td>122</td>
<td>7</td>
<td>118</td>
</tr>
<tr>
<td>Ho 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Analysis 2.4. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 4: Major bleeding

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Ho 2019</td>
<td>86</td>
<td>122</td>
<td>78</td>
<td>118</td>
</tr>
</tbody>
</table>

## Analysis 2.5. Comparison 2: Anticoagulation +/- VCF in people after multiple trauma, Outcome 5: Non major bleeding

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>VCF +/- anticoagulation</th>
<th>Anticoagulation</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Ho 2019</td>
<td>29</td>
<td>122</td>
<td>21</td>
<td>118</td>
</tr>
</tbody>
</table>

## ADDITIONAL TABLES
<table>
<thead>
<tr>
<th>Situation</th>
<th>Organisation CEP recommends</th>
<th>Organisation CEP counsels ‘consider’</th>
<th>Organisation CEP disapproves</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented VTE with contraindication to anticoagulation</td>
<td>ACCP, AHA, ACR-SIR, BSH, ESC</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Recurrent PE despite therapeutic anticoagulation</td>
<td>ACR-SIR, ESC</td>
<td>AHA</td>
<td>-</td>
</tr>
<tr>
<td>Massive PE treated with or without thrombolysis, surgical thrombectomy,</td>
<td>ACR-SIR</td>
<td>AHA</td>
<td>BSH, ESC</td>
</tr>
<tr>
<td>or adjunct to surgical thrombo-endarterectomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>‘Free-floating’ proximal thrombus</td>
<td>ACR-SIR</td>
<td>-</td>
<td>BSH, ESC</td>
</tr>
<tr>
<td>Iliocaval DVT</td>
<td>ACR-SIR, EAST</td>
<td>-</td>
<td>AHA, BSH, ESC</td>
</tr>
<tr>
<td>Documented VTE in a person with co-existing severe cardiac and/or lung</td>
<td>ACR-SIR</td>
<td>BSH, AHA</td>
<td>-</td>
</tr>
<tr>
<td>disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Documented VTE in people with cancer</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Documented VTE in pregnancy</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>People with CTEPH undergoing pulmonary thromboembolectomy</td>
<td>-</td>
<td>ACCP</td>
<td>ESC</td>
</tr>
<tr>
<td>People requiring urgent surgery, recent diagnosis of VTE (one month)</td>
<td>-</td>
<td>-</td>
<td>BSH</td>
</tr>
<tr>
<td>- retrievable filter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continued anticoagulation with filter in situ, without persistent and</td>
<td>-</td>
<td>-</td>
<td>ACCP</td>
</tr>
<tr>
<td>concurrent VTE risk factors; acute VTE episode resolved</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prophylaxis in high-risk populations (no concurrent diagnosis of VTE),</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>such as:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• severe trauma with contraindication to anticoagulation – and/or</td>
<td>-</td>
<td>ACR-SIR, EAST</td>
<td>-</td>
</tr>
<tr>
<td>significant head or spinal cord injury, or multiple long-bone and/or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pelvic fractures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• perioperative phase for bariatric surgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>• perioperative phase for orthopaedic joint replacement</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Author’s (TY) interpretation of each Organisation CEP Guidelines
ACCP: American College of Chest Physicians (ACCP 2012; ACCP 2016)
AHA: American Heart Association (AHA 2011)
ACR-SIR: American College of Radiology-Society for Interventional Radiology (ACR-SIR Practice Parameter 2014)
CEP: Consensus Expert Panel
CTEPH: chronic thromboembolic pulmonary hypertension
DVT: deep vein thrombosis
EAST: Eastern Association for the Surgery of Trauma (EAST 2002)
ESC: European Society of Cardiology (ESC 2014)
PE: pulmonary embolism
VTE: venous thromboembolism
## APPENDICES

### Appendix 1. Search strategies 3 October 2016

<table>
<thead>
<tr>
<th>Source</th>
<th>Search strategies</th>
<th>Hits retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>CENTRAL (The Cochrane Library) via The Cochrane Register of Studies Online</td>
<td>#1 MESH DESCRIPTOR Thrombosis 1233</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>#2 MESH DESCRIPTOR Thromboembolism 893</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#3 MESH DESCRIPTOR Venous Thromboembolism 234</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#4 MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES 1998</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#5 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*):TI,AB,KY 16851</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES 731</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#7 (PE or DVT or VTE):TI,AB,KY 4482</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#8 (vein* or ven*) near thromb*:TI,AB,KY 6116</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#9 (blood near3 clot*):TI,AB,KY 2561</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#10 (pulmonary near3 clot*):TI,AB,KY 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#11 (lung near3 clot*):TI,AB,KY 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 21948</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#13 MESH DESCRIPTOR Embolic Protection Devices EXPLODE ALL TREES 40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#14 (ven* near cav*):TI,AB,KY 597</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#15 Tempofilter:TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#16 VenaTech:TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#17 (Bard near G2):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#18 (Bard near Recovery):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#19 (Boston near Greenfield):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#20 (&quot;Birds Nest&quot;):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#21 (Celect near3 filter):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#22 (Tulip near3 filter):TI,AB,KY 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#23 OptEase:TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#24 TrapEase:TI,AB,KY 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#25 Mobin-Uddin:TI,AB,KY 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#26 (option or ALN) near3 filter:TI,AB,KY 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#27 (Rex Medical Option):TI,AB,KY 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#28 (Simon near Nitinol):TI,AB,KY 0</td>
<td></td>
</tr>
</tbody>
</table>
#29 IVC:TI,AB,KY 159
#30 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 706
#31 #12 AND #30 142

<table>
<thead>
<tr>
<th>Source</th>
<th>Search strategy</th>
<th>Hits retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical.trials.gov</td>
<td>vena AND filter</td>
<td>78</td>
</tr>
<tr>
<td>World Health Organization International Clinical Trials Registry</td>
<td>vena AND filter</td>
<td>37</td>
</tr>
<tr>
<td>ISRCTN Register</td>
<td>vena AND filter</td>
<td>5</td>
</tr>
<tr>
<td>Cochrane Vascular Specialised Register</td>
<td></td>
<td>16</td>
</tr>
</tbody>
</table>

**Appendix 2. Search strategies 23 October 2017**

<table>
<thead>
<tr>
<th>Source</th>
<th>Search strategy</th>
<th>Hits retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>CENTRAL (The Cochrane Library) <a href="http://cr-so.cochrane.org/SearchSimple.php">http://cr-so.cochrane.org/SearchSimple.php</a></td>
<td>#1 MESH DESCRIPTOR Thrombosis 1301</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>#2 MESH DESCRIPTOR Thromboembolism 941</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#3 MESH DESCRIPTOR Venous Thromboembolism 288</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#4 MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES 2077</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#5 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or emboli*):TI,AB,KY 20594</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES 768</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#7 (PE or DVT or VTE):TI,AB,KY 5489</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#8 (((vein* or ven*) near thromb*)):TI,AB,KY 7255</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#9 (blood near3 clot*):TI,AB,KY 3442</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#10 (pulmonary near3 clot*):TI,AB,KY 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#11 (lung near3 clot*):TI,AB,KY 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 26840</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#13 ven* near cav* 715</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#14 Tempofilter 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#15 VenaTech 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#16 Bard near G2 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#17 Bard near Recovery 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#18 Boston near Greenfield 1</td>
<td></td>
</tr>
</tbody>
</table>
(Continued)

#19 "Birds Nest" 0
#20 Celect near3 filter 0
#21 Tulip near3 filter 1
#22 OptEase 1
#23 TrapEase 1
#24 Mobin-Uddin 1
#25 (option or ALN) near3 filter 2
#26 Rex Medical Option 0
#27 Simon near Nitinol 0
#28 IVC 208
#29 MESH DESCRIPTOR Embolic Protection Devices EXPLODE ALL TREES 44
#30 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 853
#31 #12 AND #30 182
#32 2 AND 01/01/2016 TO 23/10/2017:CD 126127
#33 #31 AND #32 41

<table>
<thead>
<tr>
<th>MEDLINE In-process and other non-indexed citations and MEDLINE 1950-present (Ovid SP)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 *Thrombosis/ 46108</td>
<td>43</td>
</tr>
<tr>
<td>2 *Thromboembolism/ 14919</td>
<td></td>
</tr>
<tr>
<td>3 *Venous Thromboembolism/ 7237</td>
<td></td>
</tr>
<tr>
<td>4 exp Venous Thrombosis/ 53408</td>
<td></td>
</tr>
<tr>
<td>5 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).ti,ab. 309171</td>
<td></td>
</tr>
<tr>
<td>6 exp Pulmonary Embolism/ 37732</td>
<td></td>
</tr>
<tr>
<td>7 (PE or DVT or VTE).ti,ab. 47021</td>
<td></td>
</tr>
<tr>
<td>8 (vein* or ven*) adj thromb*.ti,ab. 62549</td>
<td></td>
</tr>
<tr>
<td>9 (blood adj3 clot*).ti,ab. 10323</td>
<td></td>
</tr>
<tr>
<td>10 (pulmonary adj3 clot*).ti,ab. 194</td>
<td></td>
</tr>
<tr>
<td>11 (lung adj3 clot*).ti,ab. 45</td>
<td></td>
</tr>
<tr>
<td>12 or/1-11 385423</td>
<td></td>
</tr>
<tr>
<td>13 exp Embolic Protection Devices/ 3144</td>
<td></td>
</tr>
<tr>
<td>14 (ven* adj cav*).ti,ab. 38025</td>
<td></td>
</tr>
<tr>
<td>15 Tempofilter.ti,ab. 15</td>
<td></td>
</tr>
<tr>
<td>16 VenaTech.ti,ab. 23</td>
<td></td>
</tr>
<tr>
<td>17 Bard near G2.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>18 (Bard adj Recovery).ti,ab. 19</td>
<td></td>
</tr>
</tbody>
</table>
19 (Boston adj Greenfield).ti,ab. 0
20 "Birds Nest".ti,ab. 211
21 (Celect adj3 filter).ti,ab. 26
22 (Tulip adj3 filter).ti,ab. 84
23 OptEase.ti,ab. 70
24 TrapEase.ti,ab. 58
25 Mobin-Uddin.ti,ab. 83
26 ((option or ALN) adj3 filter).ti,ab. 38
27 Rex Medical Option.ti,ab. 0
28 Simon near Nitinol.ti,ab. 0
29 IVC.ti,ab. 6485
30 or/13-26 39267
31 12 and 30 12034
32 randomized controlled trial.pt. 497429
33 controlled clinical trial.pt. 99269
34 randomized.ab. 434012
35 placebo.ab. 202938
36 drug therapy.fs. 2116475
37 randomly.ab. 299126
38 trial.ab. 457784
39 groups.ab. 1847670
40 or/32-39 4373745
41 31 and 40 1939
42 2017*.dc. 1013696
43 41 and 42 43

Embase
1974 to present
1 *Thrombosis/ 35969
2 *Thromboembolism/ 10153
3 *Venous Thromboembolism/ 12916
4 exp Venous Thrombosis/ 92212
5 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).ti,ab. 327639
6 exp Pulmonary Embolism/ 65195
7 (PE or DVT or VTE).ti,ab. 64224
8 ((vein* or ven*) adj thromb*).ti,ab. 72863
9 (blood adj3 clot*).ti,ab. 8974
10 (pulmonary adj3 clot*).ti,ab. 216
11 (lung adj3 clot*).ti,ab. 50
12 or/1-11 429010
13 exp Embolic Protection Devices/ 5782
14 (ven* adj cav*).ti,ab. 31153
15 Tempofilter.ti,ab. 16
16 VenaTech.ti,ab. 33
17 Bard near G2.ti,ab. 0
18 (Bard adj Recovery).ti,ab. 26
19 (Boston adj Greenfield).ti,ab. 0
20 "Birds Nest".ti,ab. 161
21 (Celect adj3 filter).ti,ab. 43
22 (Tulip adj3 filter).ti,ab. 113
23 OptEase.ti,ab. 122
24 TrapEase.ti,ab. 84
25 Mobin-Uddin.ti,ab. 10
26 ((option or ALN) adj3 filter).ti,ab. 64
27 Rex Medical Option.ti,ab. 0
28 Simon near Nitinol.ti,ab. 0
29 IVC.ti,ab. 9521
30 or/13-26 34232
31 12 and 30 12765
32 randomized controlled trial/ 430404
33 controlled clinical trial/ 405597
34 random$.ti,ab. 1116788
35 randomization/ 67742
36 intermethod comparison/ 221687
37 placebo.ti,ab. 212361
38 (compare or compared or comparison).ti. 322661
39 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab. 1536790
40 (open adj label).ti,ab. 59046
41 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. 151544
42 double blind procedure/ 117639
43 parallel group$1.ti,ab. 18719
44 (crossover or cross over).ti,ab. 69322
45 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).ti,ab. 237683
46 (assigned or allocated).ti,ab. 278807
47 (controlled adj7 (study or design or trial)).ti,ab. 249300
48 (volunteer or volunteers).ti,ab. 166367
49 trial.ti. 202856
50 or/32-49 3326430
51 2017*.dc. 1500421
52 31 and 50 and 51 157

<table>
<thead>
<tr>
<th>AMED</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).ti,ab. 631</td>
<td>0</td>
</tr>
<tr>
<td>2 exp Pulmonary Embolism/ 53</td>
<td></td>
</tr>
<tr>
<td>3 (PE or DVT or VTE).ti,ab. 240</td>
<td></td>
</tr>
<tr>
<td>4 ((vein* or ven*) adj thromb*).ti,ab. 305</td>
<td></td>
</tr>
<tr>
<td>5 (blood adj3 clot*).ti,ab. 34</td>
<td></td>
</tr>
<tr>
<td>6 (pulmonary adj3 clot*).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>7 (lung adj3 clot*).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>8 or/1-T 805</td>
<td></td>
</tr>
<tr>
<td>9 (ven* adj cav*).ti,ab. 47</td>
<td></td>
</tr>
<tr>
<td>10 Tempofilter.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>11 VenaTech.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>12 Bard near G2.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>1 (Bard adj Recovery).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>3 (Boston adj Greenfield).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>14 &quot;Birds Nest&quot;.ti,ab. 4</td>
<td></td>
</tr>
<tr>
<td>15 (Celect adj3 filter).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>16 (Tulip adj3 filter).ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>17 OptEase.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>18 TrapEase.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>19 Mobin-Uddin.ti,ab. 0</td>
<td></td>
</tr>
<tr>
<td>20 ((option or ALN) adj3 filter).ti,ab. 1</td>
<td></td>
</tr>
<tr>
<td>21 Rex Medical Option.ti,ab. 0</td>
<td></td>
</tr>
</tbody>
</table>
22 Simon near Nitinol.ti,ab. 0
23 IVC.ti,ab. 11
24 or/9-23 51
25 8 and 24 17
26 "2017".af. 66
27 24 and 26 0

CINAHL (EBSCOhost)
S40 S31 AND S32 AND S39 15
S39 S33 OR S34 OR S35 OR S36 OR S37 OR S38
S38 TX randomly
S37 TX "treatment as usual"
S36 TX "double-blind"
S35 TX "single-blind"
S34 TX trial
S33 MH "Clinical Trials"
S32 EM 2017
S31 S12 AND S30 755
S30 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 2,731
S29 Simon N1 Nitinol 1
S28 Rex Medical Option 5
S27 Rex Medical Option 0
S26 ((option or ALN) N3 filter) 8
S25 Mobin-Uddin 0
S24 TrapEase 2
S23 OptEase 2
S22 Tulip N3 filter 5
S21 Celect N3 filter 1
S20 ("Birds Nest") 1
S19 Boston N1 Greenfield 1
S18 Bard N1 Recovery 9
S17 Bard N1 Recovery 0
S16 Bard N1 G2 8
S15 Tempofilter 0
S14 Tempofilter 0
Appendix 3. Database searches

<table>
<thead>
<tr>
<th>Source</th>
<th>Version/Platform/url</th>
<th>Date of Search</th>
<th>Records retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovid MEDLINE(R) Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present</td>
<td>(Ovid SP)</td>
<td>23.10.2017</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.11.18</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.9.19</td>
<td>138</td>
</tr>
<tr>
<td>Embase</td>
<td>(Ovid SP)</td>
<td>23.10.2017</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.11.18</td>
<td>441</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.9.19</td>
<td>316</td>
</tr>
<tr>
<td>AMED</td>
<td>(Ovid SP)</td>
<td>23.10.2017</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14.11.18</td>
<td>0</td>
</tr>
</tbody>
</table>
### WHAT'S NEW

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 July 2020</td>
<td>New search has been performed</td>
<td>Searches re-run. Four new studies were included and seven new studies excluded. We identified six new ongoing studies.</td>
</tr>
<tr>
<td>10 July 2020</td>
<td>New citation required but conclusions have not changed</td>
<td>Searches re-run. Four new studies were included and seven new studies excluded. Review text was updated and 'Summary of findings' tables added to reflect current Cochrane standards. Conclusions not changed.</td>
</tr>
</tbody>
</table>

### HISTORY

Protocol first published: Issue 4, 2006  

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22 October 2009</td>
<td>New citation required but conclusions have not changed</td>
<td>John Aukes removed as author from the updated review.</td>
</tr>
<tr>
<td>Date</td>
<td>Event</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>22 October 2009</td>
<td>New search has been performed</td>
<td>Searches updated and one additional RCT included. Conclusions remain unchanged.</td>
</tr>
<tr>
<td>21 April 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>9 November 2007</td>
<td>New search has been performed</td>
<td>One additional reference (conference abstract) added to the included study (PREPIC). No change to conclusions.</td>
</tr>
<tr>
<td>22 August 2007</td>
<td>New citation required but conclusions have not changed</td>
<td>Citation order revised on request of review author.</td>
</tr>
</tbody>
</table>

**Contributions of Authors**

TY: wrote the protocol, review and update, searched for trials, contacted relevant biomedical companies and clinicians involved with filters, and obtained full-text articles, independently selected and assessed trials for inclusion and risk of bias, and assessed the certainty of the evidence using GRADE.

KBS: independently searched for trials, independently selected and assessed trials for inclusion and risk of bias, independently extracted data, and assisted in writing the review update.

**Declarations of Interest**

TY: none known

KBS: none known

**Sources of Support**

Internal sources

- No sources of support supplied

External sources

- Chief Scientist Office, Scottish Government Health Directorates, Scottish Government, UK

The editorial base of Cochrane Vascular is supported by the Chief Scientist Office.

**Differences Between Protocol and Review**

For the original review, each trial was evaluated for quality according to the Jadad scale (Jadad 1996). For this update, we used Cochrane’s ‘Risk of bias’ tool and presented the results in a ‘Summary of findings’ table.

We have added ‘major bleeding’ as an outcome, as this is a clinically relevant potential adverse effect due to the use of anticoagulation in these patients more so than the presence, or absence, of a filter.

**Index Terms**

**Medical Subject Headings (MeSH)**

- Pulmonary Embolism [mortality] [*prevention & control]; Randomized Controlled Trials as Topic; *Vena Cava Filters [adverse effects]; Vena Cava, Inferior; Venous Thrombosis [complications]

**MeSH check words**

- Humans